[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 142
1. Moon JI, Selvaggi G, Nishida S, Levi DM, Kato T, Ruiz P, Bejarano P, Madariaga JR, Tzakis AG: Intestinal transplantation for the treatment of neoplastic disease. J Surg Oncol; 2005 Dec 15;92(4):284-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: There were 25 auto- or allograft transplantations in 21 patients; desmoid tumor (14), neuroendocrine tumor (2), adenocarcinoma (2), hemangioma (1), lymphoma (1), and solid pseudopapillary tumor (1).
  • [MeSH-minor] Adolescent. Adult. Child, Preschool. Duodenum / transplantation. Female. Fibromatosis, Aggressive / pathology. Fibromatosis, Aggressive / surgery. Graft Rejection. Humans. Liver Transplantation. Male. Middle Aged. Pancreas Transplantation. Quality of Life. Recurrence. Stomach / transplantation. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2005 Dec 15;92(4):272-3 [16299793.001]
  • (PMID = 16299803.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 1 R03 DK061445-01 A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


2. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM: Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma; 2008 Oct;49(10):1893-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.
  • The transformation of follicular lymphoma (FL) to high-grade histology occurs in up to 70% of FL patients.
  • Studies reporting outcomes of transformed FL patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are scant.
  • Eight FL patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent HSCT at our institution.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Feasibility Studies. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Salvage Therapy. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Homologous


3. Gollub MJ, Hong R, Sarasohn DM, Akhurst T: Limitations of CT during PET/CT. J Nucl Med; 2007 Oct;48(10):1583-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 100 patients, the most common malignancies were lymphoma (n = 37), cancer of the colorectum (n = 31), and esophageal cancer (n = 15).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Humans. Middle Aged. Observer Variation. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873133.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Ma J, Liu YF, Chen SM, Zhang QT, Sun L, Liu LX, Wan DM, Chen SQ, Xie XS, Meng XL, Jiang ZX, Cheng YD, Wang F, Sun H: [Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):942-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages].
  • The purpose of this study was to investigate the immunophenotyping characteristics of adult acute lymphoblastic leukemia (ALL) patients in groups of different ages.
  • The results indicated that (1) all the 82 cases of T-cell acute lymphoblastic leukemia (T-ALL) expressed CD7 (100%) while the positive rate of CD2 remarkably decreased with aging.
  • Moreover, there were significant differences of the myeloid antigen (MyAg) and CD13 expression between the older adults and younger adults (p < 0.05). (2) As to adult B-cell acute lymphoblastic leukemia (B-ALL), the positive rates of CD19 and HLA-DR in 178 cases were 100%; the positive rate of CD33 in young adults was significant higher than that in adolescents (p < 0.05), the differences of the other marker expressions failed to reach statistical significance in adult B-ALL patients.
  • It is concluded that the immunophenotypes of adult T-ALL are evidently heterogeneous in different ages, and expression with more aberrant phenotypes indicates poor prognostic significance in patients older than 35 years.
  • There is no significant association of immunophenotypes with ages among different age groups of adult B-ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723305.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD2; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


5. Bi R, Lin DM, Han YL, Lu J, Xue LY, Zheng S, Wang MR, Lü N: [Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Nov;38(11):733-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma].
  • METHODS: A total of 74 fresh tissue samples clinically suspicious of lymphoma were investigated by FISH using three probes including IgH/bcl-2, IgH/CCND1 and API2/MALT1, corresponding the translocation t(14;18), t(11;14) and t(11;18) respectively.
  • RESULTS: Histological evaluation eventually confirmed that there were 62 cases of lymphoma and 12 cases of reactive lymphoid processes.
  • The translocations were detected in 7 cases in 62 cases of lymphoma: 3 demonstrated t(14;18) including 2 cases of follicular lymphomas and 1 nodular sclerosing Hodgkin lymphoma.
  • Four cases had t(11;14) including mantle cell lymphoma (2 cases), follicular lymphoma (1 case) and small cell lymphoma (1 case).
  • CONCLUSION: Interphase FISH offers useful ancillary technology that plays an important role in differential diagnosis and classification of lymphoma.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Lymphoma / diagnosis. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Diagnosis, Differential. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079011.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Russell NC, Hoelscher DM, Janszen L, Rodriguez MA: Dietary and weight changes after treatments for lymphoma. Nutr Cancer; 2007;57(2):168-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary and weight changes after treatments for lymphoma.
  • To estimate the current prevalence of overweight and any associations with self-reported changes in dietary patterns, we surveyed 141 patients who had completed treatments for lymphoma at The M. D.
  • [MeSH-major] Body Mass Index. Diet / standards. Lymphoma / therapy. Obesity / epidemiology. Perception
  • [MeSH-minor] Adult. Body Weight / drug effects. Body Weight / physiology. Cross-Sectional Studies. Edible Grain. Female. Fruit. Humans. Male. Middle Aged. Retrospective Studies. Surveys and Questionnaires. Vegetables

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Obesity.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571950.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Han DM, Chen XQ, Bai QX: [Exploration of prognostic factors in extranodal nasal-type NK/T cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):137
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Exploration of prognostic factors in extranodal nasal-type NK/T cell lymphoma].
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell. Nose Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Ferritins / blood. Hemoglobins / metabolism. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750021.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hemoglobins; 9007-73-2 / Ferritins; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


8. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol; 2006 Aug 20;24(24):3880-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
  • PURPOSE: A multicenter, single-arm study examining efficacy and toxicity of epratuzumab combined with rituximab was conducted in patients with recurrent or refractory non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Sixty-five patients were enrolled; 34 patients with follicular lymphoma (FL), 15 patients with diffuse large B-cell lymphoma (DLBCL), and 16 patients with other lymphomas.
  • Two of six patients with marginal zone lymphoma responded to treatment (one CR).
  • There was a trend for the response rates to be higher in patients with low prognostic index scores (statistically significant with respect to the Follicular Lymphoma International Prognostic Index score in FL patients), with 12 FL patients and three DLBCL patients in groups 0 to 1 having OR (CR/CRu) rates of 83% (33%) and 100% (100%), respectively.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, B-Cell / drug therapy. Sialic Acid Binding Ig-like Lectin 2 / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Drug Administration Schedule. Europe. Female. Humans. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


9. Helzlsouer KJ, VDPP Steering Committee: Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol; 2010 Jul 1;172(1):4-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP) brought together 10 cohorts to conduct a prospective study of the association between vitamin D status, measured as serum concentrations of 25-hydroxyvitamin D (25(OH)D), and the development of 7 rarer cancer sites: endometrial, esophageal, gastric, kidney, non-Hodgkin lymphoma, ovarian, and pancreatic cancers.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Rev. 2007 Aug;65(8 Pt 2):S71-137 [17933025.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1889-93 [17855710.001]
  • [Cites] Arch Intern Med. 2008 Aug 11;168(15):1629-37 [18695076.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1581-91 [19001601.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1439-47 [19208842.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):58-69 [20562184.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):81-93 [20562185.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):70-80 [20562186.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):47-57 [20562187.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):10-20 [20562188.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):36-46 [20562189.001]
  • [Cites] Curr Rheumatol Rep. 2008 Apr;10(2):110-7 [18460265.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):123-8 [17551495.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):21-35 [20562191.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):94-106 [20562192.001]
  • [Cites] Am J Clin Nutr. 1995 Dec;62(6 Suppl):1427S-1430S [7495243.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 6;88(21):1550-9 [8901853.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 6;88(21):1560-70 [8901854.001]
  • [CommentIn] Am J Epidemiol. 2010 Nov 15;172(10):1210-1; author reply 1211-2 [20826709.001]
  • [CommentIn] Am J Epidemiol. 2010 Jul 1;172(1):1-3 [20562190.001]
  • (PMID = 20562193.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CP / N02-CP-11010-66; United States / CCR NIH HHS / RC / N01-RC-45035; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CA / N01 CN25514; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / PC / N01-PC35137; United States / NCI NIH HHS / CA / R37 CA70867; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / R37 CA070867; United States / NCI NIH HHS / CA / N01 CN25524; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / N01 CN25513; United States / NCI NIH HHS / CA / R01 CA49449; United States / NCI NIH HHS / CA / P01 CA33619; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R37 CA54281; United States / CCR NIH HHS / RC / N01-RC-37004; United States / NCI NIH HHS / CA / N01 CN75022; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / N01 CN25512; United States / NCI NIH HHS / CN / N01-CN-45165; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / P01 CA033619; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / N01 CN25518; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CA / R01 CA82729; United States / NCI NIH HHS / CA / N01 CN25516; United States / NCI NIH HHS / CA / N01 CN25511; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CA / R01 CA105069; United States / NCI NIH HHS / CA / N01 CN25476; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01 CN045165; United States / NCI NIH HHS / CP / N02CP11010; United States / NCI NIH HHS / CA / N01 CN25522; United States / NCI NIH HHS / CA / N01 CN25515; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NIA NIH HHS / AG / U01 AG018033; United States / NCI NIH HHS / CN / N01-CN-25522; United States / NCI NIH HHS / CA / K07 CA73790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2892542
  • [Investigator] Abnet CC; Albanes D; Freedman DM; Gallicchio L; Hankinson SE; Hartge P; Hartmuller V; Harvey C; Helzlsouer KJ; Horst RL; Kolonel LN; Laden F; McCullough ML; Purdue MP; Shu XO; Snyder K; Stolzenberg-Solomon RZ; Weinstein SJ; Yu K; Zeleniuch-Jacquotte A; Zheng W
  •  go-up   go-down


10. O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM, Lister TA, Fitzgibbon J: Array-based DNA methylation profiling in follicular lymphoma. Leukemia; 2009 Oct;23(10):1858-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-based DNA methylation profiling in follicular lymphoma.
  • Quantitative methylation profiling was performed using the Illumina GoldenGate Assay in untreated follicular lymphoma (FL) (164), paired pre- and post-transformation FL (20), benign haematopoietic (24) samples and purified B and T cells from two FL cases.
  • [MeSH-major] DNA Methylation. Gene Expression Profiling. Lymph Nodes / pathology. Lymphoma, Follicular / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. CpG Islands. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3060-71 [15126342.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):919-25 [3284977.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1459-65 [15902285.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):430-9 [16191512.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):149-53 [16444255.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):738-40 [16804535.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1075-83 [16899657.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1855-62 [16900213.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1658-60 [17041636.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1443-4 [17047192.001]
  • [Cites] Mol Cancer. 2006;5:44 [17026765.001]
  • [Cites] Curr Pharm Biotechnol. 2006 Oct;7(5):315-21 [17076647.001]
  • [Cites] Leukemia. 2007 Jan;21(1):18-29 [17039231.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52 [17023173.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):391-403 [17272646.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1040-3 [17457052.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1514-20 [17495976.001]
  • [Cites] Nat Protoc. 2007;2(9):2265-75 [17853883.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8511-8 [17875690.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1083-94 [17825402.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1304-15 [17999367.001]
  • [Cites] PLoS One. 2007;2(12):e1289 [18074014.001]
  • [Cites] Genome Res. 2008 May;18(5):780-90 [18316654.001]
  • [Cites] Leukemia. 2008 May;22(5):1035-43 [18288132.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10280-9 [19074896.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):758-64 [19155300.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2298-301 [19141865.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Haematologica. 2004 Feb;89(2):154-64 [15003890.001]
  • (PMID = 19587707.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United Kingdom / Cancer Research UK / / A9424; United Kingdom / Cancer Research UK / / A8314; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / 5 U01 CA114778; United Kingdom / Cancer Research UK / / MONG1E9R
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2762475; NLM/ UKMS4607
  •  go-up   go-down


11. Toledo RA, Mendonca BB, Fragoso MC, Soares IC, Almeida MQ, Moraes MB, Lourenço DM Jr, Alves VA, Bronstein MD, Toledo SP: Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis. Clinics (Sao Paulo); 2010 Apr;65(4):407-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequently, the mother developed a large virilizing adrenocortical carcinoma and a grade II B-cell non-Hodgkin's lymphoma.
  • No evidence of LOH was observed in the DNA sample from the mother's B-cell lymphoma, and this tumor displayed normal AIP immunostaining.
  • [MeSH-minor] Adolescent. Adult. Female. Gene Expression. Genes, p53. Germ-Line Mutation. Humans. Loss of Heterozygosity / genetics. Multiple Endocrine Neoplasia Type 1 / genetics. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2008 Sep;159(3):259-74 [18524795.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Mar;95(3):1318-27 [20080836.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] Cell Stress Chaperones. 2000 Jul;5(3):243-54 [11005382.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):542-4 [11158006.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 [11600572.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Am J Hum Genet. 2002 Dec;71(6):1433-42 [12424709.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5658-61 [12466368.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33351-63 [12810716.001]
  • [Cites] Eur J Endocrinol. 2004 May;150(5):643-8 [15132719.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):216-9 [9920087.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):730-5 [10022445.001]
  • [Cites] Pituitary. 2004;7(2):95-101 [15761658.001]
  • [Cites] Clinics (Sao Paulo). 2006 Feb;61(1):59-70 [16532227.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2006 Feb;50(1):7-16 [16628270.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2558-73 [17167139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4101-5 [17360484.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Apr;66(4):499-502 [17371465.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13656-63 [17329248.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1891-6 [17244780.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1952-5 [17299063.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1934-7 [17341560.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):1-8 [17609395.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Sep;67(3):377-84 [17555499.001]
  • [Cites] Clinics (Sao Paulo). 2007 Aug;62(4):465-76 [17823710.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):750-2 [18272904.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401 [18381572.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 Feb;70(2):259-64 [18710468.001]
  • [Cites] Horm Res. 2009 Apr;71 Suppl 2:116-22 [19407507.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • (PMID = 20454499.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  • [Other-IDs] NLM/ PMC2862671
  • [Keywords] NOTNLM ; AIP / Acromegaly / Adrenocortical tumor / FIPA / pituitary tumor
  •  go-up   go-down


12. Zarebska-Michaluk DA, Lebensztejn DM, Kryczka WM, Skiba E: Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. Adv Med Sci; 2010;55(1):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 210 patients with CHC (61.7%) presented at least 1 extrahepatic manifestation, including mixed cryoglobulinemia (37.1%), thrombocytopenia (27.6%), thyroid autoimmunity (16.2%), dermatological disorders (4.1%) and type 2 diabetes (4.1%).
  • Other EM such as the sicca syndrome, nephropathy, polyneuropathy and B-cell lymphoma were observed in single cases.
  • [MeSH-minor] Adolescent. Adult. Aged. Autoimmunity / physiology. Cryoglobulinemia / etiology. Cryoglobulinemia / pathology. Humans. Male. Middle Aged. Multivariate Analysis. Poland. Thrombocytopenia / etiology. Thrombocytopenia / pathology. Young Adult


13. Sitas F, Parkin DM, Chirenje M, Stein L, Abratt R, Wabinga H: Part II: Cancer in Indigenous Africans--causes and control. Lancet Oncol; 2008 Aug;9(8):786-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, we review the current knowledge of causes of some of the leading cancers in Africa, namely cancers of the cervix, breast, liver, prostate, stomach, bladder, and oesophagus, Kaposi's sarcoma, non-Hodgkin lymphoma, and tobacco-related cancers.
  • [MeSH-minor] Adult. Africa / epidemiology. Age Distribution. Aged. Developing Countries. Female. Humans. Incidence. Male. Mass Screening / organization & administration. Middle Aged. Poverty. Primary Prevention / organization & administration. Risk Assessment. Sex Distribution. Socioeconomic Factors. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672214.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 86
  •  go-up   go-down


14. Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA: Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev; 2006 Apr;15(4):630-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study.
  • Because lymphoma comprises numerous histologic subtypes, understanding the reasons for ongoing increases in its incidence requires surveillance and etiologic study of these subtypes.
  • Studies including patients diagnosed before 2001 may have codes from earlier ICD-O versions that must be converted to ICD-O-3 and have higher proportions of unclassified (e.g., lymphoma and not otherwise specified) cases.
  • To better understand (a) the agreement of computer-converted ICD-O-3 codes to ICD-O-3 codes generated directly from diagnostic pathology reports and (b) the reproducibility of unclassified status, we reviewed a population-based series of diagnostic pathology reports for lymphoma patients diagnosed before (1988-1994; n = 1,493) and after (1998-2000; n = 1,527) the REAL/WHO scheme was introduced.
  • The most common lymphoma subtypes, diffuse large B cell and follicular, had relatively good reliability (84-89%) throughout the study period.
  • T-cell and natural killer cell lymphomas had worse agreement than B-cell lymphomas, even when grouped.
  • These findings suggest that the study of lymphoma subtypes could be improved by (a) use of more standardized terminology in pathology reports, (b) grouping individual ICD-O-3 codes to reduce misclassification bias, and (c) routine secondary editing of unclassified lymphomas by central cancer registries.
  • [MeSH-major] Lymphoma / classification. Lymphoma / epidemiology. Population Surveillance / methods. SEER Program
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. International Classification of Diseases. Male. Middle Aged. Registries. Reproducibility of Results. San Francisco / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614102.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA45614; United States / NCI NIH HHS / CA / CA66529; United States / NCI NIH HHS / CA / CA89745; United States / NCI NIH HHS / CN / N01-CN-65107
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


15. Israel R, Dorer R, Aboulafia DM: Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy. Am J Med Sci; 2010 Feb;339(2):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy.
  • As the incidence of human immunodeficiency virus (HIV) infection in women of child bearing age continues to increase in the era of highly active antiretroviral therapy and Hodgkin lymphoma (HL) is the most common non-acquired immunodeficiency syndrome defining malignancy, we anticipate that the number of cases of HIV-associated HL in pregnant women will increase in the near future.
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Humans. Viral Load


16. Chiu A, Frizzera G, Mathew S, Hyjek EM, Chadburn A, Tam W, Knowles DM, Orazi A: Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. Mod Pathol; 2009 Nov;22(11):1507-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma.
  • Among the diffuse lymphomas of B-cell origin, we have encountered one variant displaying blastoid features that morphologically mimic lymphoblastic lymphoma, the blastoid variant of mantle cell lymphoma, and the so-called blastoid transformation of follicular lymphoma.
  • To better characterize this entity, we studied eight cases morphologically, immunohistochemically, and by fluorescence in situ hybridization (FISH) for cytogenetic abnormalities commonly associated with follicular lymphoma and B-cell lymphomas exhibiting high-grade histological features.
  • All eight cases were presented as de novo neoplasms, and displayed an entirely diffuse (five cases) or only minimal follicular (three cases) growth pattern.
  • The neoplastic lymphoid cells were of medium size with round nuclei, fine chromatin, inconspicuous nucleoli, and high mitotic rate; they expressed CD10, BCL6, and BCL2-a phenotype consistent with follicle center cell origin.
  • Their lack of TdT and CYCLIN D1 distinguished them from lymphoblastic lymphoma and the blastoid mantle cell lymphoma, respectively.
  • The neoplastic lymphoid cells consistently expressed CD43 (seven of eight cases) and occasionally other T-cell-associated antigens, including CD5, CD7, CD8, and CD57.
  • The combination of a B-cell CD10+ BCL6+ BCL2+ phenotype in the presence of structural abnormalities of BCL6 is consistent with a follicular center cell derivation for our cases.
  • The lack of t(14;18) seen in our cases, although rare in most cases of follicular lymphoma, has been nevertheless reported in cases of follicular lymphoma with a predominantly diffuse growth pattern.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 18 / genetics. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. B-Lymphocytes / metabolism. Cytogenetic Analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Interferon Regulatory Factors / genetics. Interferon Regulatory Factors / metabolism. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633642.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / interferon regulatory factor-4
  •  go-up   go-down


17. Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC: Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol; 2010 Jul;150(2):189-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
  • Targeting aberrant DNA hypermethylation in chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) with decitabine may reverse epigenetic silencing in B-cell malignancies.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):87-91 [12708480.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2424-33 [15059895.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2928-35 [15131027.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4347-53 [10361133.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):265-74 [15723065.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3877-85 [15809452.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]
  • [Cites] Br J Cancer. 2005 Dec 12;93(12):1388-94 [16333246.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):653-8 [16423993.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(7):1117-26 [16523529.001]
  • [Cites] Haematologica. 2006 Jul;91(7):895-902 [16818276.001]
  • [Cites] Blood. 2007 Jan 1;109(1):52-7 [16882708.001]
  • [Cites] Nucleic Acids Res. 2007;35(5):e31 [17264127.001]
  • [Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] Biochem Pharmacol. 2008 Feb 15;75(4):857-65 [18078872.001]
  • [Cites] Blood. 2009 Jan 15;113(3):659-67 [18931345.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3881-8 [19470736.001]
  • (PMID = 20456354.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109004-01A1; United States / NCI NIH HHS / CA / P01 CA101956; United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / U01 CA076576; United States / NCI NIH HHS / CA / K23 CA109004; United States / NCI NIH HHS / CA / P30 CA016058; None / None / / K23 CA109004-01A1; United States / NCI NIH HHS / CA / U01 CA76576
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS216448; NLM/ PMC2917115
  •  go-up   go-down


18. McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flanders WD, Koenig K, Kolonel L, Laden F, Le Marchand L, Purdue M, Snyder K, Stevens VL, Stolzenberg-Solomon R, Virtamo J, Yang G, Yu K, Zheng W, Albanes D, Ashby J, Bertrand K, Cai H, Chen Y, Gallicchio L, Giovannucci E, Jacobs EJ, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Shu XO: Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol; 2010 Jul 1;172(1):21-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
  • Low vitamin D status is common globally and is associated with multiple disease outcomes.
  • Understanding the correlates of vitamin D status will help guide clinical practice, research, and interpretation of studies.
  • Correlates of circulating 25-hydroxyvitamin D (25(OH)D) concentrations measured in a single laboratory were examined in 4,723 cancer-free men and women from 10 cohorts participating in the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, which covers a worldwide geographic area.
  • Demographic and lifestyle characteristics were examined in relation to 25(OH)D using stepwise linear regression and polytomous logistic regression.
  • The prevalence of 25(OH)D concentrations less than 25 nmol/L ranged from 3% to 36% across cohorts, and the prevalence of 25(OH)D concentrations less than 50 nmol/L ranged from 29% to 82%.
  • Seasonal differences in circulating 25(OH)D were most marked among whites from northern latitudes.
  • Statistically significant positive correlates of 25(OH)D included male sex, summer blood draw, vigorous physical activity, vitamin D intake, fish intake, multivitamin use, and calcium supplement use.
  • Significant inverse correlates were body mass index, winter and spring blood draw, history of diabetes, sedentary behavior, smoking, and black race/ethnicity.
  • Correlates varied somewhat within season, race/ethnicity, and sex.
  • These findings help identify persons at risk for low vitamin D status for both clinical and research purposes.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Osteoporos Int. 1998;8(3):222-30 [9797906.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):10-20 [20562188.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [15585788.001]
  • [Cites] J Nutr. 2005 Feb;135(2):317-22 [15671234.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):635-40 [15546897.001]
  • [Cites] Eur J Clin Nutr. 2005 Apr;59(4):533-41 [15714215.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24 [15797954.001]
  • [Cites] Prev Med. 2005 Jul;41(1):108-17 [15917001.001]
  • [Cites] Diabetes Care. 2006 Mar;29(3):650-6 [16505521.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Osteoporos Int. 2006;17(8):1133-40 [16718398.001]
  • [Cites] Am J Clin Nutr. 2007 Mar;85(3):755-61 [17344497.001]
  • [Cites] Am J Clin Nutr. 2007 Mar;85(3):860-8 [17344510.001]
  • [Cites] Am J Clin Nutr. 2007 Jun;85(6):1586-91 [17556697.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Nutr Rev. 2007 Aug;65(8 Pt 2):S124-6 [17867388.001]
  • [Cites] Am J Clin Nutr. 2007 Oct;86(4):959-64 [17921371.001]
  • [Cites] Am J Clin Nutr. 2007 Nov;86(5):1399-404 [17991652.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):232-8 [18199729.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Mar;68(3):466-72 [17941903.001]
  • [Cites] Am J Clin Nutr. 2008 Mar;87(3):608-13 [18326598.001]
  • [Cites] Br J Nutr. 2008 May;99(5):1061-7 [18197989.001]
  • [Cites] Bone. 2008 May;42(5):996-1003 [18329355.001]
  • [Cites] Cancer Causes Control. 2008 Jun;19(5):527-35 [18219582.001]
  • [Cites] Am J Clin Nutr. 2008 Aug;88(2):541S-544S [18689398.001]
  • [Cites] Eur J Clin Nutr. 2008 Sep;62(9):1079-89 [17538533.001]
  • [Cites] Am J Epidemiol. 2008 Sep 15;168(6):577-86; discussion 587-91 [18579538.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Oct;69(4):535-41 [18331609.001]
  • [Cites] Am J Clin Nutr. 2008 Dec;88(6):1519-27 [19064511.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] Eur J Clin Nutr. 2009 Apr;63(4):458-64 [18030310.001]
  • [Cites] BMC Public Health. 2009;9:191 [19534831.001]
  • [Cites] Am J Clin Nutr. 2000 Sep;72(3):690-3 [10966885.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4125-30 [11095443.001]
  • [Cites] Br J Nutr. 2001 Aug;86 Suppl 1:S97-103 [11520426.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):337-44 [11790213.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] Am J Clin Nutr. 2002 Jul;76(1):187-92 [12081833.001]
  • [Cites] Br J Nutr. 2002 Nov;88(5):555-61 [12425736.001]
  • [Cites] Public Health Nutr. 2004 Apr;7(2):327-35 [15003141.001]
  • [Cites] Am J Clin Nutr. 1986 Apr;43(4):621-8 [3485918.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • [Cites] Am J Clin Nutr. 1987 Dec;46(6):1005-10 [3687818.001]
  • [Cites] Arch Dermatol. 1991 Apr;127(4):536-8 [1848745.001]
  • [Cites] Am J Clin Nutr. 1997 Oct;66(4):929-36 [9322570.001]
  • [Cites] Clin Biochem. 2009 Oct;42(15):1549-56 [19631201.001]
  • [Cites] Maturitas. 2010 Mar;65(3):225-36 [20031348.001]
  • [Cites] Eur J Clin Nutr. 2010 Mar;64(3):280-8 [20051977.001]
  • [Cites] J Nutr. 1999 Apr;129(4):855-64 [10203561.001]
  • (PMID = 20562191.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CP / N02-CP-11010-66; United States / CCR NIH HHS / RC / N01-RC-45035; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CA / N01 CN25514; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / CA / R37 CA70867; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / R37 CA070867; United States / NCI NIH HHS / CA / N01 CN25524; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / N01 CN25513; United States / NCI NIH HHS / CA / R01 CA49449; United States / NCI NIH HHS / CA / P01 CA33619; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R37 CA54281; United States / CCR NIH HHS / RC / N01-RC-37004; United States / NCI NIH HHS / CA / N01 CN75022; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / N01 CN25512; United States / NCI NIH HHS / PC / N01- PC35137; United States / NCI NIH HHS / CN / N01-CN-45165; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / P01 CA033619; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / N01 CN25518; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CA / R01 CA82729; United States / NCI NIH HHS / CA / N01 CN25516; United States / NCI NIH HHS / CA / N01 CN25511; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CA / R01 CA105069; United States / NCI NIH HHS / CA / N01 CN25476; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01 CN045165; United States / NCI NIH HHS / CP / N02CP11010; United States / NCI NIH HHS / CA / N01 CN25522; United States / NCI NIH HHS / CA / N01 CN25515; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NIA NIH HHS / AG / U01 AG018033; United States / NCI NIH HHS / CN / N01-CN-25522; United States / NCI NIH HHS / CA / K07 CA73790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2892536
  •  go-up   go-down


19. Madson DM, Opriessnig T: Multicentric T-cell lymphosarcoma in a white-tailed deer (Odocoileus virginianus). J Wildl Dis; 2009 Jul;45(3):791-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric T-cell lymphosarcoma in a white-tailed deer (Odocoileus virginianus).
  • An adult female white-tailed deer (Odocoileus virginianus) with a history of shaking, ataxia, and severe debilitation was submitted for examination.
  • Similar lymphoblasts were associated with the leptomeninges, choroid plexus, and the intestinal mucosa; these cells were intensely positive for CD3 antigen, indicating their T-cell origin.
  • [MeSH-major] Deer. Lymphoma, T-Cell / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617490.001).
  • [ISSN] 0090-3558
  • [Journal-full-title] Journal of wildlife diseases
  • [ISO-abbreviation] J. Wildl. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W, Severson RK, Davis S: Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control; 2006 Oct;17(8):1045-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States).
  • OBJECTIVE: Because of conflicting findings about the relationship between ultraviolet (UV) radiation and the risk of non-Hodgkin lymphoma (NHL), we evaluated the risk of several indicators related to UV, including two not previously studied: dietary vitamin D, and ambient UV levels by residential location.
  • Effects were generally similar for diffuse large B-cell (DLBCL) and follicular lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Ultraviolet Rays. Vitamin D / administration & dosage. Vitamin D / pharmacology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Confidence Intervals. Female. Humans. Interviews as Topic. Male. Middle Aged. Risk Factors. Surveys and Questionnaires. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933055.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / CP / N02-CP-31003; United States / NCI NIH HHS / PC / N02-PC-71105; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  •  go-up   go-down


21. Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, Spalding C, Hughes S, Pittaluga S, Raffeld M, Sorbara LR, Elloumi HZ, Kuhns DB, Turner ML, Cowen EW, Fink D, Long-Priel D, Hsu AP, Ding L, Paulson ML, Whitney AR, Sampaio EP, Frucht DM, DeLeo FR, Holland SM: Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood; 2010 Feb 25;115(8):1519-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia.
  • We identified 18 patients with the distinct clinical phenotype of susceptibility to disseminated nontuberculous mycobacterial infections, viral infections, especially with human papillomaviruses, and fungal infections, primarily histoplasmosis, and molds.
  • This syndrome typically had its onset in adulthood (age range, 7-60 years; mean, 31.1 years; median, 32 years) and was characterized by profound circulating monocytopenia (mean, 13.3 cells/microL; median, 14.5 cells/microL), B lymphocytopenia (mean, 9.4 cells/microL; median, 4 cells/microL), and NK lymphocytopenia (mean, 16 cells/microL; median, 5.5 cells/microL).
  • T lymphocytes were variably affected.
  • Despite these peripheral cytopenias, all patients had macrophages and plasma cells at sites of inflammation and normal immunoglobulin levels.
  • Ten of these patients developed 1 or more of the following malignancies: 9 myelodysplasia/leukemia, 1 vulvar carcinoma and metastatic melanoma, 1 cervical carcinoma, 1 Bowen disease of the vulva, and 1 multiple Epstein-Barr virus(+) leiomyosarcoma.
  • Five patients developed pulmonary alveolar proteinosis without mutations in the granulocyte-macrophage colony-stimulating factor receptor or anti-granulocyte-macrophage colony-stimulating factor autoantibodies.
  • Among these 18 patients, 5 families had 2 generations affected, suggesting autosomal dominant transmission as well as sporadic cases.
  • This novel clinical syndrome links susceptibility to mycobacterial, viral, and fungal infections with malignancy and can be transmitted in an autosomal dominant pattern.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2007 Apr;26(4):390-2 [17459807.001]
  • [Cites] Pathol Biol (Paris). 2007 Feb;55(1):37-48 [16697122.001]
  • [Cites] Immunol Res. 2007;38(1-3):342-6 [17917041.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6816-28 [17934488.001]
  • [Cites] Curr Treat Options Oncol. 2007 Apr;8(2):129-34 [17926010.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1350-7 [18042691.001]
  • [Cites] Br J Haematol. 2008 Jan;140(2):123-32 [18173751.001]
  • [Cites] Curr Opin Immunol. 2008 Feb;20(1):52-60 [18160272.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Apr;38(4):380-5 [18192503.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Apr 1;177(7):752-62 [18202348.001]
  • [Cites] Blood. 2008 May 15;111(10):4841-51 [18467609.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):66-70 [18085671.001]
  • [Cites] Immunol Invest. 2008;37(5):467-81 [18716934.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7693-706 [18829521.001]
  • [Cites] J Allergy Clin Immunol. 2008 Dec;122(6):1043-51; quiz 1052-3 [19084105.001]
  • [Cites] Virology. 2009 Feb 20;384(2):260-5 [19135222.001]
  • [Cites] PLoS One. 2009;4(4):e5210 [19381294.001]
  • [Cites] Clin Infect Dis. 2009 Jul 1;49(1):102-11 [19489714.001]
  • [Cites] Science. 1976 Jun 4;192(4243):1016-8 [775638.001]
  • [Cites] Clin Immunol. 2000 May;95(2):85-92 [10779401.001]
  • [Cites] Immunol Lett. 2000 May 1;72(2):75-82 [10841941.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):658-62 [10934102.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] J Infect. 2001 Apr;42(3):213-4 [11545557.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):591-5 [12007507.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jul 15;166(2):215-35 [12119235.001]
  • [Cites] Front Biosci. 2002 Oct 1;7:d2058-71 [12165480.001]
  • [Cites] Microbes Infect. 2002 Dec;4(15):1545-58 [12505527.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):33-40 [12670463.001]
  • [Cites] Thorax. 2003 Jul;58(7):645 [12832691.001]
  • [Cites] Am J Hematol. 2003 Nov;74(3):221-3 [14587059.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):155-8 [14734230.001]
  • [Cites] J Pediatr. 2004 Apr;144(4):519-23 [15069403.001]
  • [Cites] Stem Cells. 2004;22(4):590-9 [15277704.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Am J Kidney Dis. 2004 Sep;44(3):556-8 [15332229.001]
  • [Cites] J Exp Med. 1978 Jul 1;148(1):1-17 [670884.001]
  • [Cites] Science. 1978 Sep 8;201(4359):937-8 [356266.001]
  • [Cites] Blood. 1979 Mar;53(3):412-36 [367468.001]
  • [Cites] Lab Invest. 1982 Feb;46(2):165-70 [6174824.001]
  • [Cites] Cancer. 1982 May 1;49(9):1924-8 [7074589.001]
  • [Cites] Scand J Haematol. 1982 Aug;29(2):153-60 [6753123.001]
  • [Cites] J Exp Med. 1984 Nov 1;160(5):1273-83 [6491600.001]
  • [Cites] J Leukoc Biol. 1987 Nov;42(5):443-6 [3316460.001]
  • [Cites] J Allergy Clin Immunol. 1990 Feb;85(2):453-9 [2303649.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):731 [1355830.001]
  • [Cites] N Engl J Med. 1994 May 12;330(19):1348-55 [7908719.001]
  • [Cites] Respir Med. 1996 Nov;90(10):641-2 [8959124.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2211-7 [9410898.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [9636188.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):875-80 [10499925.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2521-5 [15621772.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4769-76 [16177125.001]
  • [Cites] Am J Hum Genet. 2006 Apr;78(4):721-7 [16532402.001]
  • [Cites] Genes Dev. 2006 Nov 1;20(21):3010-21 [17079688.001]
  • [Cites] J Infect Chemother. 2006 Oct;12(5):331-4 [17109096.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2000-7 [17277103.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3488-94 [17785782.001]
  • (PMID = 20040766.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ; Canada / Canadian Institutes of Health Research / / ; United States / NCI NIH HHS / CA / N01CO12400; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CA / HHSN261200800001E
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2830758
  •  go-up   go-down


22. Paulsson K, Cazier JB, Macdougall F, Stevens J, Stasevich I, Vrcelj N, Chaplin T, Lillington DM, Lister TA, Young BD: Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A; 2008 May 06;105(18):6708-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.
  • Importantly, the pattern of deletions resembled that recently reported in pediatric ALL, suggesting that adult, adolescent, and childhood cases may be more similar on the genetic level than previously thought.
  • Our findings provide insights into the leukemogenic process and may be clinically important in adult and adolescent ALL.
  • [MeSH-major] Gene Deletion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. B-Lymphocytes / pathology. Cell Cycle / genetics. Child. Chromosome Aberrations. Genes, Neoplasm. Genome, Human / genetics. Humans. Lymphopoiesis / genetics. Middle Aged. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):176-8 [16213368.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2006 May;20(5):840-6 [16498392.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):748-56 [16470520.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Ann Oncol. 2007 Jan;18 Suppl 1:i3-i8 [17311819.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2327-30 [17095619.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Cancer. 2007 May 15;109(10):2058-67 [17407135.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4306-18 [17237825.001]
  • [Cites] Hum Mol Genet. 2007 Sep 15;16(18):2215-25 [17613536.001]
  • [Cites] Immunol Cell Biol. 2008 Jan;86(1):47-53 [17998914.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):729-39 [18506749.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1976-82 [11064355.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Ann Med. 2004;36(7):492-503 [15513300.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Jul;16(3):155-63 [8814447.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • (PMID = 18458336.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE9611
  • [Grant] United Kingdom / Cancer Research UK / / A6438; United Kingdom / Cancer Research UK / / A6789
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373322
  •  go-up   go-down


23. Aboulafia DM, Puswella AL: Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS; 2007 Dec;21(12):900-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment.
  • A brain imaging study showed a right temporal mass, which on biopsy proved to be primary central nervous system lymphoma (PCNSL).
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male


24. Ruggero K, Corradin A, Zanovello P, Amadori A, Bronte V, Ciminale V, D'Agostino DM: Role of microRNAs in HTLV-1 infection and transformation. Mol Aspects Med; 2010 Oct;31(5):367-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus that infects more than 20 million people worldwide, is the etiological agent of ATLL (adult T-cell leukemia/lymphoma), an aggressive leukemia of CD4+ T lymphocytes which arises in a small percentage of infected individuals after a long clinical latency.
  • Tumor emergence is attributed primarily to the oncogenic activity of the viral protein Tax, which drives the expression of viral transcripts and controls the expression and function of a broad variety of host-cell genes involved in proliferation, genetic stability and apoptosis.
  • In the present review we discuss recent data demonstrating changes in cellular microRNA expression in HTLV-1-infected cell lines and ATLL cells, and the functional impact of a subset microRNAs deregulated by HTLV-1 on cellular gene expression and signal transduction pathways.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. HTLV-I Infections / genetics. Human T-lymphotropic virus 1 / pathogenicity. Human T-lymphotropic virus 1 / physiology. MicroRNAs / metabolism
  • [MeSH-minor] Gene Expression Regulation, Leukemic / genetics. Humans. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20600265.001).
  • [ISSN] 1872-9452
  • [Journal-full-title] Molecular aspects of medicine
  • [ISO-abbreviation] Mol. Aspects Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


25. Barclay LR, Buskin SE, Kahle EM, Aboulafia DM: Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma Myeloma; 2007 Jan;7(4):272-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy.
  • Despite the decrease in HIV-associated morbidity and mortality with the advent of highly active antiretroviral therapy (HAART), the incidence of AIDS-related lymphoma (ARL) has not decreased as significantly.
  • We used the Adult and Adolescent Spectrum of HIV-Related Diseases database of Public Health-Seattle and King County to determine incidences and trends among patients with ARL in Seattle/King County, WA.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324334.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 30
  •  go-up   go-down


26. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, Workneh M, Coutinho A, Engels EA: Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer; 2006 Feb 15;118(4):985-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk was increased in the early-incident period, compared to the general population, for the AIDS-defining cancers: Kaposi sarcoma (SIR 6.4, 95%CI 4.8-8.4), non-Hodgkin lymphoma (6.7, 1.8-17), and cervical carcinoma (2.4, 1.1-4.4).
  • Risks of five non-AIDS-defining cancers were increased in the combined periods: Hodgkin lymphoma (5.7, 1.2-17) and cancers of the conjunctiva (SIR 4.0; 1.5-8.7), kidney (16, 1.8-58), thyroid (5.7, 1.1-16), and uterus (5.5, 1.5-14).
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Prevalence. Risk Factors. Uganda / epidemiology


27. Ren LQ, Xue LY, Bi R, Liang JM, Lin DM, Ma J, Lü N: [Application of flow cytometric immunophenotypic analysis in the diagnosis of malignant lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct;28(10):671-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of flow cytometric immunophenotypic analysis in the diagnosis of malignant lymphoma].
  • OBJECTIVE: To explore the value of flow cytometric immunophenotyping (FCI) in the diagnosis and differentiated diagnosis of lymphoma and explain the immunophenotypic features and differences of malignant lymphoma.
  • METHODS: Seventy four fresh samples of suspicious lymphoma were collected from Nov.
  • For the diagnosis of B and T non-Hodgkin's lymphoma (NHL), thymoma, carcinoma and benign lesions of lymph node, the concordance between FCI data and morphological diagnosis were 93.5%, 100%, 100%, 100% and 81.3%, respectively.
  • CONCLUSION: Multi-parameter FCI analysis can provide important information and help for diagnosis of lymphoma.
  • It is an assistant but necessary approach for the diagnosis and differential diagnosis of lymphoma.
  • [MeSH-major] Flow Cytometry. Immunophenotyping / methods. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399172.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G: Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol; 2008 Sep-Oct;26(5):887-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.
  • RESULTS: Two patients with Jo-1 antibody positive dermatomyositis (DM) demonstrated a clinical response.
  • Re-evaluation of three patients revealed that one had inclusion body myositis, one had sporadic muscular dystrophy and one subsequently developed nodular sclerosing lymphoma.
  • All except one patient showed adequate B cell depletion with re-population occurring 3- >42 months after BCDT.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Muscle Strength. Rituximab

  • Genetic Alliance. consumer health - Idiopathic myopathy.
  • MedlinePlus Health Information. consumer health - Myositis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032824.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


29. Plasschaert SL, de Bont ES, Boezen M, vander Kolk DM, Daenen SM, Faber KN, Kamps WA, de Vries EG, Vellenga E: Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res; 2005 Dec 15;11(24 Pt 1):8661-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia.
  • [MeSH-major] Multidrug Resistance-Associated Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Child. Female. Gene Expression. Humans. Male. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism. RNA, Neoplasm / chemistry. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361551.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


30. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE: HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol; 2007 Jan;20(1):54-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target.
  • HDM4 expression in most cases of adult pre-B ALL suggests that HDM4 is a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / pathology. Nuclear Proteins / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mutation. Philadelphia Chromosome. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins c-mdm2 / analysis. RNA, Messenger / analysis. Time Factors. Treatment Outcome. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143258.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / MDM4 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


31. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM: HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis; 2006 Nov 1;43(9):1198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to describe the laboratory findings and clinical course of MGUS, including association with plasma cell disorders, other malignancies, and infections, in 25 HIV-infected patients with a detectable serum monoclonal protein.
  • Laboratory studies included determination of CD4(+) T lymphocyte cell counts, HIV type 1 loads, and quantitative immunoglobulin levels; serum and urine protein immunoelectrophoresis; and determination of serum viscosity indices.
  • After a mean follow-up duration of 21 months, 7 patients (28%) received a diagnosis of a malignancy (multiple myeloma, in 1 patient; non-Hodgkin lymphoma, in 1; Hodgkin lymphoma, in 1; Kaposi sarcoma, in 2; and plasmacytoma, in 2).
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active / adverse effects. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Lymphoma, AIDS-Related / complications. Male. Middle Aged. Retrospective Studies. Sarcoma, Kaposi / complications


32. Feng H, Langenau DM, Madge JA, Quinkertz A, Gutierrez A, Neuberg DS, Kanki JP, Look AT: Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish. Br J Haematol; 2007 Jul;138(2):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish.
  • The zebrafish is an ideal vertebrate model system to investigate the complex genetic basis of cancer because it has the capacity for in vivo tumour-cell imaging and forward genetic screens, and the molecular mechanisms regulating malignancy are remarkably conserved when compared with human.
  • Our laboratory has previously generated transgenic zebrafish models that overexpress the mouse c-Myc gene fused to enhanced green fluorescent protein (EGFP) and develop T-cell acute lymphoblastic leukaemia (T-ALL) that recapitulates the human disease both molecularly and pathologically.
  • After heat-shock treatment at 3 d postfertilisation (dpf) for 45 min at 37 degrees C, 81% of compound transgenic fish developed T-lymphoblastic lymphoma (T-LBL, mean latency 120 +/- 43 (standard deviation) days of life), which rapidly progressed to T-ALL.
  • [MeSH-major] HSP70 Heat-Shock Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell / genetics

  • COS Scholar Universe. author profiles.
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593023.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-119066; United States / NCI NIH HHS / CA / CA-68484; United States / NHLBI NIH HHS / HL / T32-HL007574
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / HSP70 Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


33. Shah MH, Freud AG, Benson DM Jr, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA: A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res; 2006 Jul 1;12(13):3993-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
  • PURPOSE: Ultra low doses of interleukin-2 (IL-2) can activate the high-affinity IL-2 receptor constitutively expressed on CD56(bright) natural killer (NK) cells, the CD34+ NK cell precursor, and CD4+ CD25+ regulatory T cells (Tregs) in vivo.
  • We have previously shown synergy between IL-2 and stem cell factor (SCF) in the generation of CD56(bright) NK cells from CD34+ hemopoietic progenitor cells in vitro and showed synergistic NK cell expansion in an in vivo preclinical model.
  • CONCLUSIONS: Administration of IL-2 with SCF is safe and well tolerated and leads to expansion of lymphocyte subsets in patients with HIV or HIV and cancer; however, the changes in NK cell and Treg expansion seen with this cytokine combination were no different than those seen with a similar dose of IL-2 alone.
  • [MeSH-major] Colonic Neoplasms / drug therapy. HIV / drug effects. HIV Infections / drug therapy. Interleukin-2 / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Stem Cell Factor / administration & dosage
  • [MeSH-minor] Adult. Antigens, CD56 / immunology. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Humans. Infusions, Intravenous. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Maximum Tolerated Dose. Middle Aged. Remission Induction. T-Lymphocytes, Regulatory / drug effects. T-Lymphocytes, Regulatory / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818697.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA70079; United States / NCI NIH HHS / CA / CA91683; United States / NCI NIH HHS / CA / CA95426
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Interleukin-2; 0 / Stem Cell Factor
  •  go-up   go-down


34. Collenberg E, Ouedraogo T, Ganamé J, Fickenscher H, Kynast-Wolf G, Becher H, Kouyaté B, Kräusslich HG, Sangaré L, Tebit DM: Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. J Med Virol; 2006 May;78(5):683-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A seroprevalence study was carried out of six different human pathogenic viruses, namely human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-cell leukemia virus (HTLV), human herpesvirus type 8 (HHV-8), and dengue virus among pregnant women and blood donors from rural (Nouna) and urban (Ouagadougou) Burkina Faso, West Africa.
  • [MeSH-major] Antibodies, Viral / blood. Blood Donors. Dengue / epidemiology. Dengue Virus / immunology. HIV Infections / epidemiology. HTLV-I Infections / epidemiology. Hepatitis C / epidemiology. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / immunology. Lymphoma, T-Cell / epidemiology. Pregnancy Complications, Infectious / epidemiology
  • [MeSH-minor] Adolescent. Adult. Burkina Faso / epidemiology. Comorbidity. Female. HIV Antibodies / blood. HTLV-I Antibodies / blood. Hepatitis C Antibodies / blood. Humans. Male. Middle Aged. Pregnancy. Seroepidemiologic Studies


35. Silic-Benussi M, Biasiotto R, Andresen V, Franchini G, D'Agostino DM, Ciminale V: HTLV-1 p13, a small protein with a busy agenda. Mol Aspects Med; 2010 Oct;31(5):350-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1) infection is characterized by life-long persistence of the virus in the host.
  • While most infected individuals remain asymptomatic, 3-5% will eventually develop adult T-cell leukemia/lymphoma (ATLL) or tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) after a clinical latency that can span years (TSP/HAM) to decades (ATLL).
  • The major oncogenic determinant among HTLV-1 proteins is the Tax transactivator, which influences the expression and function of a great number of cellular proteins, drives cell proliferation, reduces cell death, and induces genetic instability.
  • These effects are linked to the protein's effects on cell turnover which include activation of primary T-cells and reduced proliferation/sensitization to death of tumor cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1765-70 [11080824.001]
  • [Cites] Retrovirology. 2009;6:102 [19903329.001]
  • [Cites] J Virol. 2001 Aug;75(16):7672-82 [11462039.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1150-9 [11493464.001]
  • [Cites] J Virol. 2002 Feb;76(3):1400-14 [11773414.001]
  • [Cites] Mol Immunol. 2002 Feb;38(10):723-32 [11841832.001]
  • [Cites] J Virol. 2002 Apr;76(7):3493-501 [11884573.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):352-3 [11925557.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3562-71 [12068005.001]
  • [Cites] J Virol. 2002 Aug;76(15):7843-54 [12097596.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34424-33 [12093802.001]
  • [Cites] J Virol. 2002 Oct;76(20):10374-82 [12239314.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6629-34 [15100416.001]
  • [Cites] Arch Biochem Biophys. 2004 Sep 15;429(2):123-33 [15313215.001]
  • [Cites] Free Radic Biol Med. 2004 Oct 15;37(8):1144-51 [15451054.001]
  • [Cites] J Virol. 1990 Nov;64(11):5682-7 [1976827.001]
  • [Cites] Adv Cancer Res. 1991;57:381-411 [1659124.001]
  • [Cites] J Virol. 1993 Apr;67(4):2360-6 [8445734.001]
  • [Cites] Immunol Lett. 1996 Dec;54(2-3):67-71 [9052856.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):3050-5 [9743370.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1341-9 [10022816.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4505-14 [10442641.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:871-7 [15846376.001]
  • [Cites] J Virol. 2005 Aug;79(15):9449-57 [16014908.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2181-91 [16314839.001]
  • [Cites] Blood. 2006 May 15;107(10):3933-9 [16403915.001]
  • [Cites] J Biol Chem. 2006 Dec 1;281(48):37150-8 [17008317.001]
  • [Cites] Science. 2007 Jan 12;315(5809):201-5 [17218518.001]
  • [Cites] Leukemia. 2007 Feb;21(2):261-9 [17122865.001]
  • [Cites] Apoptosis. 2007 May;12(5):815-33 [17294078.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):409-13 [17508027.001]
  • [Cites] Cell Death Differ. 2007 Jul;14(7):1267-74 [17431419.001]
  • [Cites] Nat Rev Immunol. 2007 Jul;7(7):532-42 [17589543.001]
  • [Cites] Free Radic Biol Med. 2007 Sep 15;43(6):861-8 [17697931.001]
  • [Cites] Nature. 2008 Jan 31;451(7178):591-5 [18235503.001]
  • [Cites] Nat Med. 2008 Apr;14(4):429-36 [18376405.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:3338-51 [19273278.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1787(7):947-54 [19366603.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jul;8(7):579-91 [19478820.001]
  • [Cites] J Virol. 2001 Jul;75(13):6086-94 [11390610.001]
  • (PMID = 20332002.001).
  • [ISSN] 1872-9452
  • [Journal-full-title] Molecular aspects of medicine
  • [ISO-abbreviation] Mol. Aspects Med.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Viral Proteins
  • [Other-IDs] NLM/ NIHMS198167; NLM/ PMC2941701
  •  go-up   go-down


36. Head BP, Patel HH, Roth DM, Murray F, Swaney JS, Niesman IR, Farquhar MG, Insel PA: Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components. J Biol Chem; 2006 Sep 8;281(36):26391-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Depolymerization of microtubules with colchicine (Colch) or actin microfilaments with cytochalasin D (CD) dramatically reduced the amount of caveolin-3 in buoyant (sucrose density) fractions of adult rat cardiac myocytes.
  • Treatment of S49 T-lymphoma cells (which possess lipid rafts but lack caveolae) with CD or Colch redistributed a lipid raft marker (linker for activation of T cells (LAT)) and Galpha(s) from lipid raft domains.
  • [MeSH-minor] Adrenergic beta-Agonists / metabolism. Animals. Caveolins / genetics. Caveolins / metabolism. Cell Fractionation. Cells, Cultured. Colchicine / metabolism. Contractile Proteins / metabolism. Cyclic AMP / metabolism. Cytochalasin D / metabolism. Cytoskeleton / metabolism. Filamins. Isoproterenol / metabolism. Male. Mice. Mice, Knockout. Microfilament Proteins / metabolism. Models, Biological. Myocytes, Cardiac / metabolism. Myocytes, Cardiac / ultrastructure. Nucleic Acid Synthesis Inhibitors / metabolism. Protein Isoforms / genetics. Protein Isoforms / metabolism. Rats. Rats, Sprague-Dawley. Receptors, Adrenergic, beta / metabolism. Receptors, G-Protein-Coupled / metabolism. Sarcolemma / metabolism. Sarcolemma / ultrastructure. Tubulin Modulators / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTOCHALASIN D .
  • Hazardous Substances Data Bank. COLCHICINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818493.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM66232; United States / NHLBI NIH HHS / HL / HL66941
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Adrenergic beta-Agonists; 0 / Caveolins; 0 / Contractile Proteins; 0 / Filamins; 0 / Microfilament Proteins; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Protein Isoforms; 0 / Receptors, Adrenergic, beta; 0 / Receptors, G-Protein-Coupled; 0 / Tubulin Modulators; 22144-77-0 / Cytochalasin D; E0399OZS9N / Cyclic AMP; EC 4.6.1.1 / Adenylyl Cyclases; L628TT009W / Isoproterenol; SML2Y3J35T / Colchicine
  •  go-up   go-down


37. Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol; 2006 Mar;126(3):575-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
  • Denileukin diftitox (Ontak), a recombinant fusion protein of diphtheria toxin and ligand, IL-2, binds to the IL-2 receptor, is internalized, and causes cell death.
  • Denileukin diftitox was approved for the treatment of cutaneous T-cell lymphomas (CTCLs) with CD25+ expression.
  • Advanced TNM (T3 or T4) was significantly associated with intermediate-grade (P = 0.002) and large-cell transformation histology (P = 0.04).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Receptors, Interleukin-2 / analysis. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD30 / analysis. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Recombinant Fusion Proteins / therapeutic use. Skin / pathology. Tetrahydronaphthalenes / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410787.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672-22; United States / NCI NIH HHS / CA / K24 CA 86815; United States / NCI NIH HHS / CA / R21-CA74117
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / Tetrahydronaphthalenes; 25E79B5CTM / denileukin diftitox; A61RXM4375 / bexarotene; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


38. Ortega MM, Faria RM, Shitara ES, Assis AM, Albuquerque DM, Oliveira JS, Noguti MA, Faria JR, Costa FF, Lima CS: N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma. Leuk Lymphoma; 2006 Feb;47(2):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brazil / epidemiology. Exons. Female. Humans. Male. Middle Aged. Point Mutation. Polymerase Chain Reaction / methods. Prevalence

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321859.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, Kokia E, Shalev V: Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection; 2008 Jun;36(3):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Studies showed that diabetes mellitus (DM) is often accompanied by impaired cell-mediated immunity, which potentially may increase the risk for infectious diseases, including herpes zoster (HZ).
  • However, data on the relation between DM and HZ are scarce.
  • This case-control study explored the association between DM and HZ.
  • Personal data on history of DM, lymphoma, leukemia, or AIDS, were obtained from computerized medical records.
  • RESULTS: Adjusted analyses showed that the risk of HZ was associated with history of leukemia, lymphoma, use of steroids or antineoplastic medications, and AIDS, particularly among patients below 45 years of age.
  • In a multivariate analysis, DM was associated with an increased risk of HZ (OR=1.53; 95% CI: 1.44-1.62).
  • CONCLUSIONS: The data suggest that individuals with DM are at increased risk of HZ.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Incidence. Israel / epidemiology. Male. Middle Aged. Population Surveillance. Risk Factors


40. Bradford PT, Freedman DM, Goldstein AM, Tucker MA: Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol; 2010 Mar;146(3):265-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively).
  • [MeSH-minor] Adult. Breast Neoplasms / epidemiology. Breast Neoplasms / etiology. Female. Follow-Up Studies. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / etiology. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / etiology. Retrospective Studies. Risk Factors. Time Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1997 Oct;24(5):504-14 [9344316.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):776-9 [9311593.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1282-91 [9762927.001]
  • [Cites] Melanoma Res. 1998 Aug;8(4):361-6 [9764812.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):314-7 [10495422.001]
  • [Cites] Cancer. 1952 Nov;5(6):1110-5 [12998017.001]
  • [Cites] Cancer. 1953 Jan;6(1):1-45 [13009650.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):28-44 [15617989.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):608-21 [16054572.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2208-12 [16172233.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2040-59 [16125929.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):433-8 [16618861.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):485-8 [16618869.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Melanoma Res. 2009 Feb;19(1):24-30 [19430403.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):920-5 [19578364.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):915-9 [19578365.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):705-11 [10560858.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2252-8 [10590365.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] Br J Dermatol. 2001 Dec;145(6):981-5 [11899153.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3192-209 [12115352.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3992-6 [12124332.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3042-52 [12789279.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):562-70 [12879474.001]
  • [Cites] Eur J Cancer Prev. 2004 Feb;13(1):33-7 [15075786.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):792-4 [15252852.001]
  • [Cites] Arch Dermatol. 1975 May;111(5):603-9 [1130805.001]
  • [Cites] Tumori. 1976 Jan-Feb;62(1):127-30 [1014112.001]
  • [Cites] Lancet. 1981 May 30;1(8231):1196-9 [6112537.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:161-89 [4088297.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:361-88 [4088310.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):831-7 [3395962.001]
  • [Cites] J Gerontol. 1990 May;45(3):M108-12 [2335720.001]
  • [Cites] Br J Dermatol. 1990 Apr;122 Suppl 35:77-81 [2337529.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):660-5 [2065289.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1911-6 [1525766.001]
  • [Cites] Epidemiology. 1993 Jan;4(1):43-7 [8420580.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):751-8 [8431856.001]
  • [Cites] Surgery. 1993 Mar;113(3):330-9 [8441968.001]
  • [Cites] J Natl Cancer Inst. 1993 Dec 1;85(23):1932-7 [8230284.001]
  • [Cites] J Am Acad Dermatol. 1994 Aug;31(2 Pt 1):216-9 [8040404.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):773-9 [7790110.001]
  • [Cites] Br J Cancer. 1996 Jan;73(2):255-9 [8546916.001]
  • [Cites] Melanoma Res. 1995 Dec;5(6):433-8 [8589618.001]
  • [Cites] Ann Surg Oncol. 1997 Jan;4(1):19-23 [8985513.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] J Am Acad Dermatol. 1998 Sep;39(3):422-7 [9738776.001]
  • (PMID = 20231496.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-15
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS281491; NLM/ PMC3076705
  •  go-up   go-down


41. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT: Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant; 2008 Jan;14(1):59-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
  • Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients.
  • High-dose chemotherapy and autologous stem cell transplantation (AuSCT), moreover, has resulted in sustained complete remissions in selected patients with recurrent chemosensitive disease.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158962.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA070062; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01CA083216; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA070054; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / R01 CA095423; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / U01CA083035; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  • [Other-IDs] NLM/ NIHMS281894; NLM/ PMC4524737
  •  go-up   go-down


42. Pomerantz RG, Campbell LS, Jukic DM, Geskin LJ: Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. Arch Dermatol; 2010 May;146(5):513-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk.
  • BACKGROUND: Cutaneous T-cell lymphoma occurring in the context of posttransplant immunosuppression is rare, with 27 cases documented to date.
  • OBSERVATIONS: We report 2 new cases of posttransplant cutaneous T-cell lymphoma in patients treated at our institution.
  • CONCLUSIONS: These cases underscore the association of posttransplant cutaneous T-cell lymphoma with renal transplantation, cyclosporine and tacrolimus therapy, male sex, and later onset compared with B-cell posttransplant lymphoproliferative disease.
  • Relative to the general population, the incidence of cutaneous T-cell lymphoma seems increased among transplant recipients receiving immunosuppressive medications.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Kidney Transplantation / methods. Lymphoma, T-Cell, Cutaneous / chemically induced. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Aged. Calcineurin Inhibitors. Cyclosporine / adverse effects. Cyclosporine / therapeutic use. Humans. Male. Risk Factors. Sex Factors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479299.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


43. Liang J, Newman JG, Frank DM, Chalian AA: Cervical unicentric Castleman disease presenting as a neck mass: case report and review of the literature. Ear Nose Throat J; 2009 May;88(5):E8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Castleman disease may be mistaken for a malignant process such as lymphoma, it is a benign condition that is curable with complete surgical resection.
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444782.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


44. Haque T, Johannessen I, Dombagoda D, Sengupta C, Burns DM, Bird P, Hale G, Mieli-Vergani G, Crawford DH: A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J Infect Dis; 2006 Sep 1;194(5):584-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purified 72A1 MAb was infused into 1 healthy adult and 4 EBV-seronegative children after liver transplant.
  • No adverse reactions were seen in the adult or in 3 of the transplant recipients.
  • [MeSH-minor] Adult. Animals. Burkitt Lymphoma / immunology. Burkitt Lymphoma / prevention & control. Humans. Mice. Mice, SCID

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897655.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


45. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Positron-Emission Tomography. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


46. Ochenrider MG, Patterson DJ, Aboulafia DM: Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):144-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
  • Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of peripheral T-cell lymphoma.
  • He died 7 months after diagnosis from chemotherapy-refractory lymphoma.
  • [MeSH-major] Antibodies, Monoclonal. Crohn Disease / drug therapy. Liver Neoplasms / chemically induced. Lymphoma, T-Cell / chemically induced. Splenic Neoplasms / chemically induced
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adalimumab. Adolescent. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Azathioprine / therapeutic use. Fatal Outcome. Humans. Infliximab. Leukemia-Lymphoma, Adult T-Cell / chemically induced. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell, Peripheral / chemically induced. Lymphoma, T-Cell, Peripheral / drug therapy. Male. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371449.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; E7WED276I5 / 6-Mercaptopurine; FYS6T7F842 / Adalimumab; MRK240IY2L / Azathioprine
  • [Number-of-references] 24
  •  go-up   go-down


47. Wohltmann WE, MacAlpine DM, Hodson DS: Palmoplantar keratoderma as the initial sign in a peripheral T-cell lymphoma. Dermatol Online J; 2010;16(5):3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palmoplantar keratoderma as the initial sign in a peripheral T-cell lymphoma.
  • A 27-year-old male with an acquired severe, diffuse palmoplantar keratoderma as the initial sign of peripheral T-cell lymphoma is reported.
  • [MeSH-major] Keratoderma, Palmoplantar, Diffuse / complications. Lymphoma, T-Cell, Peripheral / complications. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Skin / pathology

  • Genetic Alliance. consumer health - Palmoplantar Keratoderma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492820.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Hu S, Granter SR, Haynes HA, Miller DM: Skin spicules: A newly described paraneoplastic phenomenon associated with a marginal zone B-cell lymphoma. J Am Acad Dermatol; 2009 May;60(5):852-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin spicules: A newly described paraneoplastic phenomenon associated with a marginal zone B-cell lymphoma.
  • We report an unusual variant of the sign of Leser-Trélat in a patient with a low-grade B-cell lymphoproliferative disorder and intertriginous skin spicules with histologic morphology of minute seborrheic keratoses.
  • [MeSH-major] Keratosis, Seborrheic / pathology. Lymphoma, B-Cell / pathology. Paraneoplastic Syndromes / pathology. Skin Diseases / pathology
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19389527.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Greenfield DM, Wright J, Brown JE, Hancock BW, Davies HA, O'Toole L, Eiser C, Coleman RE, Ross RJ: High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening. Br J Cancer; 2006 Feb 27;94(4):469-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening.
  • Assessment of late effects in a cohort of female Hodgkin's lymphoma patients treated with mantle radiotherapy, identified from the DoH breast cancer screening recall showed high mortality and frequent undiagnosed abnormalities in tissues affected by radiotherapy.
  • [MeSH-minor] Adult. Breast Neoplasms / diagnosis. Female. Follow-Up Studies. Humans. Incidence. Mass Screening. Middle Aged. Morbidity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):498-509 [10653865.001]
  • [Cites] Ann Oncol. 1996;7 Suppl 4:115-26 [8836422.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3484-94 [12177110.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):536-44 [9469338.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):240-8 [9473759.001]
  • [Cites] Haematologica. 1998 Sep;83(9):812-23 [9825578.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):418-24 [16106249.001]
  • [Cites] Lancet Oncol. 2003 Apr;4(4):207-14 [12681264.001]
  • [Cites] JAMA. 2003 Jul 23;290(4):465-75 [12876089.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4386-94 [14645429.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):294-8 [14735166.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [Cites] Acta Haematol. 2004;112(3):148-51 [15345897.001]
  • [Cites] Ann Intern Med. 2004 Oct 19;141(8):590-7 [15492338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1925-31 [3932270.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):355-63 [2261376.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):908-12 [1616862.001]
  • [Cites] Ann Oncol. 1992 Jun;3(6):455-61 [1498064.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):25-31 [8416252.001]
  • [Cites] JAMA. 1993 Oct 27;270(16):1949-55 [8411552.001]
  • [Cites] N Engl J Med. 1996 Mar 21;334(12):745-51 [8592547.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • (PMID = 16465193.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361189
  •  go-up   go-down


50. Alm El-Din MA, Hughes KS, Finkelstein DM, Betts KA, Yock TI, Tarbell NJ, Aisenberg AC, Taghian AG: Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter.
  • PURPOSE: To evaluate the risk of breast cancer (BC) and the contributing risk factors in women after supradiaphragmatic irradiation (SDI) for Hodgkin's lymphoma (HL).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Comorbidity. Female. Humans. Incidence. Massachusetts / epidemiology. Middle Aged. Retrospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538497.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009337
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE: Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol; 2006 Jul;19(7):891-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation.
  • B-cell lymphoma 10 (BCL-10) is expressed in the cytoplasm of normal germinal center and marginal zone B-cells and is involved in lymphocyte development and activation.
  • Aberrant nuclear expression of BCL-10 occurs in a subset of extranodal marginal zone B-cell lymphomas (MALT lymphomas), primarily those with the t(1;14)(p22;q32) or t(11;18)(q21;q21).
  • Little is known about BCL-10 expression in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM).
  • These results indicate that nuclear BCL-10 expression is common in LPL/WM and does not correlate with MALT lymphoma-associated translocations or p65 NF-kappaB nuclear staining.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Bone Marrow / metabolism. Cell Nucleus / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Transcription Factor RelA / metabolism. Waldenstrom Macroglobulinemia / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytoplasm / metabolism. Female. Humans. Immunoglobulin M / blood. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636680.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 0 / Immunoglobulin M; 0 / RELA protein, human; 0 / Transcription Factor RelA
  •  go-up   go-down


52. Kim HY, Oh SY, Lee S, Lee DM, Kim SH, Kwon HC, Hong SH, Yoon JH, Kim HJ: Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy. Acta Haematol; 2008;120(3):150-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy.
  • Primary penile lymphoma is rarely observed in cases of extranodal malignant lymphoma.
  • Histopathological examination of the excisional biopsy revealed CD20+ diffuse large B cell lymphoma.
  • The patient was classified as having a stage I(AE) lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large B-Cell, Diffuse / therapy. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19039206.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


53. Fonseca Junior NL, Paves L, Nakanami DM, Seixas MT, Manso PG: [Orbital granulocytic sarcoma: case report]. Arq Bras Oftalmol; 2005 Jul-Aug;68(4):557-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcoma is most frequently confused with malignant lymphoma, rhabdomyosarcoma and neuroblastoma.
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Female. Humans. Leukemia, Myeloid / complications. Leukemia, Myeloid / pathology. Magnetic Resonance Spectroscopy. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322847.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


54. Lowenthal RM, Tuck DM, Bray IC: Residential exposure to electric power transmission lines and risk of lymphoproliferative and myeloproliferative disorders: a case-control study. Intern Med J; 2007 Sep;37(9):614-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Case-control study of 854 patients diagnosed with LPD or MPD (including leukaemia, lymphoma and related conditions) aged 0-94 years comprising all cases diagnosed in Tasmania between 1972 and 1980.
  • RESULTS: Compared with those who had always lived >300 m from a power line, those who had ever lived within 50 m had an odds ratio (OR) of 2.06 (95% confidence interval 0.87-4.91) for developing LPD or MPD (based on 768 adult case-control pairs); those who had lived between 50 and 300 m had an OR of 1.30 (0.88-1.91).
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Risk Factors. Tasmania / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Electromagnetic Fields.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med J. 2008 Sep;38(9):746; author reply 746-7 [19143897.001]
  • [CommentIn] Intern Med J. 2007 Dec;37(12):841 [18028096.001]
  • (PMID = 17543004.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


55. Linet MS, Freedman DM, Mohan AK, Doody MM, Ron E, Mabuchi K, Alexander BH, Sigurdson A, Hauptmann M: Incidence of haematopoietic malignancies in US radiologic technologists. Occup Environ Med; 2005 Dec;62(12):861-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Working as a radiologic technologist was not significantly linked with risk of multiple myeloma (28 cases), non-Hodgkin's lymphoma (118 cases), Hodgkin's lymphoma (31 cases), or chronic lymphocytic leukaemia (23 cases).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Radiol Prot. 2000 Dec;20(4):353-9 [11140709.001]
  • [Cites] Nucleonics. 1949 Dec;5(6):63-6 [15394470.001]
  • [Cites] Health Phys. 2002 Apr;82(4):455-66 [11906134.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):259-67 [12455042.001]
  • [Cites] Semin Ultrasound CT MR. 2002 Oct;23(5):428-42 [12509113.001]
  • [Cites] Am J Epidemiol. 1975 Mar;101(3):199-210 [1115059.001]
  • [Cites] Radiology. 1978 Mar;126(3):677-9 [628739.001]
  • [Cites] Br J Radiol. 1981 Mar;54(639):187-94 [7470779.001]
  • [Cites] JAMA. 1990 Aug 1;264(5):601-4 [2366300.001]
  • [Cites] Br J Radiol. 1991 May;64(761):455-60 [2036572.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):586-98 [1728391.001]
  • [Cites] Radiat Res. 1995 Apr;142(1):1-11 [7899552.001]
  • [Cites] Radiat Res. 1995 May;142(2):117-32 [7724726.001]
  • [Cites] Radiat Res. 1995 Nov;144(2):160-9 [7480642.001]
  • [Cites] Am J Epidemiol. 1997 Jan 1;145(1):72-80 [8982025.001]
  • [Cites] J Radiol Prot. 1999 Mar;19(1):3-26 [10321692.001]
  • [Cites] J Epidemiol. 1999 Apr;9(2):61-72 [10337078.001]
  • [Cites] Radiat Res. 1999 Sep;152(3):280-92 [10453089.001]
  • [Cites] Radiology. 1953 Feb;60(2):186-91 [13112398.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1957 Dec;78(6):988-92 [13478785.001]
  • [Cites] Science. 1963 Dec 13;142(3598):1492-4 [14077037.001]
  • [Cites] Br J Radiol. 2001 Jun;74(882):507-19 [11459730.001]
  • (PMID = 16299095.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-15673; United States / NCI NIH HHS / CP / N01-CP-51016; United States / NCI NIH HHS / CP / N02-CP-81005; United States / NCI NIH HHS / CP / N02-CP-81121
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1740936
  •  go-up   go-down


56. Davis JL, Miller DM, Ruiz P: Diagnostic testing of vitrectomy specimens. Am J Ophthalmol; 2005 Nov;140(5):822-829
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the usefulness of diagnostic tests that are performed on vitrectomy specimens from patients with suspected lymphoma or infection.
  • RESULTS: There were 28 patients (33 eyes) with suspected intraocular lymphoma and 50 patients (51 eyes) with suspected infection, which was subdivided into chronic endogenous endophthalmitis, atypical chorioretinitis, or chronic postoperative inflammation.
  • Vitreous testing led to a diagnosis in 48 of 78 patients (61.5%); 14 patients with a final diagnosis of lymphoma/leukemia, and 34 patients with a final diagnosis of infection.
  • For lymphoma, the PPV of cytologic evaluation was 100% and the NPV 60.9%.
  • CD22+ B lymphocytes >or=20% of total cells on cytofluorographic analysis had a PPV of 88% for lymphoma.
  • CONCLUSION: Diagnostic vitrectomy in selected patients with carefully planned testing is an effective means of supporting diagnoses in intraocular lymphoma, chronic intraocular infections, and atypical chorioretinitis.
  • Flow cytometry quantitates the percentages and ratios of various cell types and is helpful in contrasting intraocular lymphoma with immunologically mediated uveitis.
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / pathology. Bacteriological Techniques. CD4-CD8 Ratio. Diagnostic Techniques, Ophthalmological. Endophthalmitis / diagnosis. Endophthalmitis / microbiology. False Negative Reactions. Female. Flow Cytometry. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Middle Aged. Polymerase Chain Reaction. Predictive Value of Tests. Retrospective Studies. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2006 May;141(5):982; author reply 982-3 [16678533.001]
  • (PMID = 16310459.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Ojha J, Islam N, Cohen DM, Marshal D, Reavis MR, Bhattacharyya I: Post-transplant lymphoproliferative disorders of oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 May;105(5):589-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is characterized histologically by abnormal lymphoid cell proliferation.
  • Although many forms of PTLD do not meet all of the histologic criteria of lymphoma, they often behave clinically in a malignant fashion if left untreated.
  • [MeSH-minor] Adult. Child. DNA, Viral / analysis. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18442744.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immunosuppressive Agents
  • [Number-of-references] 33
  •  go-up   go-down


58. Khan M, Mori M, Fujino Y, Shibata A, Sakauchi F, Washio M, Tamakoshi A, Japan Collaborative Cohort Study Group: Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev; 2006 Apr-Jun;7(2):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study examined the association of diabetes mellitus (DM) history with total and common site-specific cancers using a large cohort of 23,378 men and 33,503 women, extracted from 127,477 healthy participants of the JACC Study who were aged 40-79 years and living in 24 municipalities in Japan.
  • At enrollment during 1988-90, each subject completed a self-administered questionnaire including items for age, sex, body mass index (BMI), smoking, drinking, past history of DM and cancer.
  • A history of DM was reported by 7.5% of men and 4.6% of women.
  • DM significantly increased the risk of liver cancer for both men (IRR=2.30; 95%CI=1.47-3.59) and women (IRR=2.70; 95%CI=1.20-6.05).
  • Significant increased and reduced risk due to DM for men were also found for non-Hodgkin lymphoma (IRR=2.77; 95%CI=1.04-7.38) and stomach cancer (IRR=0.67; 95%CI=0.46-0.99) respectively.
  • For females, a reduced risk of stomach cancer due to DM (IRR=0.49; 95%CI=0.23-1.04) was also revealed.
  • Since a history of DM here demonstrated significant associations with some site-specific cancers, their relationships should be studied further in Japan for validation.
  • [MeSH-minor] Adult. Age Distribution. Aged. Body Mass Index. Cohort Studies. Female. Health Surveys. Humans. Incidence. Japan / epidemiology. Life Style. Male. Middle Aged. Risk Factors. Sex Distribution

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839219.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Thailand
  •  go-up   go-down


59. Dominguez FJ, Lawrence C, Halpern EF, Drohan B, Grinstein G, Black DM, Smith BL, Gadd MA, Specht M, Kopans DB, Moore RH, Hughes SS, Roche CA, Hughes KS: Accuracy of self-reported personal history of cancer in an outpatient breast center. J Genet Couns; 2007 Jun;16(3):341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The accuracy for breast cancer and Hodgkin's Lymphoma was significantly better than other cancers (p=0.00027, CI: 1.4-3.88).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / genetics. Cross-Sectional Studies. Female. Humans. Microcomputers. Middle Aged. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / genetics. Registries. Sensitivity and Specificity. Software. Surveys and Questionnaires. Uterine Neoplasms / epidemiology. Uterine Neoplasms / genetics


60. Cozen W, Hamilton AS, Zhao P, Salam MT, Deapen DM, Nathwani BN, Weiss LM, Mack TM: A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood; 2009 Nov 5;114(19):4014-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.
  • The pattern of adolescent/young adult Hodgkin lymphoma (YAHL) suggests causation by a relatively late infection with a common childhood virus, but no causal virus has been found.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Am J Epidemiol. 2002 Dec 1;156(11):1011-20 [12446257.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] N Engl J Med. 2003 Jun 5;348(23):2313-22 [12788995.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S27-32 [15202522.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] J Natl Cancer Inst. 1973 Jun;50(6):1429-35 [4717560.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Br Med J. 1978 Feb 11;1(6109):327-9 [623979.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4507-11 [498082.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] J Clin Epidemiol. 1989;42(12):1207-13 [2585011.001]
  • [Cites] J Clin Gastroenterol. 1990 Apr;12(2):127-9 [2157745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):977-81 [9378561.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1045-7 [9569037.001]
  • [Cites] Clin Exp Allergy. 1999 Mar;29(3):342-6 [10202341.001]
  • [Cites] Lancet. 1999 Sep;354 Suppl 2:SII12-5 [10507253.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):617-22 [15622446.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):89-93 [16309494.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):251-6 [16533224.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Neurology. 2007 Jul 24;69(4):381-8 [17646631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1561-6 [17684129.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3377-82 [18077789.001]
  • [Cites] BMC Immunol. 2008;9:65 [18990206.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1590-6 [11069568.001]
  • (PMID = 19738032.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836-01A2; United States / NCI NIH HHS / CA / R03CA110836-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2774542
  •  go-up   go-down


61. Mulrooney DA, Ness KK, Neglia JP, Whitton JA, Green DM, Zeltzer LK, Robison LL, Mertens AC: Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS). Sleep; 2008 Feb;31(2):271-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS).
  • STUDY OBJECTIVE: To examine the prevalence of and risk factors for fatigue and sleep disturbance among adult survivors of childhood cancer.
  • PARTICIPANTS: Two thousand six hundred forty-five survivors of childhood acute lymphocytic leukemia, central nervous system tumors, Hodgkin lymphoma, soft-tissue sarcomas, or bone tumors diagnosed before age 21, surviving at least 5 years from diagnosis, and a 500-sibling comparison group.
  • CONCLUSION: Because of the large sample size, we detected more objectively reported fatigue, sleep disturbance, and daytime sleepiness among adult survivors of childhood cancer.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Jan;39(2):204-14 [12509953.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Oncologist. 2003;8 Suppl 1:5-9 [12626781.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1249-54 [12663711.001]
  • [Cites] J Pain Symptom Manage. 2003 Apr;25(4):307-18 [12691682.001]
  • [Cites] Pediatrics. 2003 Jul;112(1 Pt 1):e46-54 [12837905.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2179-86 [14522376.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):503-10 [15080780.001]
  • [Cites] Psychiatry Res. 1989 May;28(2):193-213 [2748771.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] J Pain Symptom Manage. 2000 Feb;19(2):91-9 [10699536.001]
  • [Cites] J Pain Symptom Manage. 2000 Jul;20(1):12-8 [10946164.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):971-5 [11038033.001]
  • [Cites] Support Care Cancer. 2001 Jan;9(1):11-7 [11147137.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):895-908 [11157043.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3385-91 [11454886.001]
  • [Cites] J Child Neurol. 2001 Oct;16(10):767-70 [11669353.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):528-38 [11900238.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3993-6 [12161549.001]
  • [Cites] Am J Obstet Gynecol. 2002 Oct;187(4):1070-80 [12389007.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2431-41 [12436452.001]
  • [Cites] Sleep. 1991 Dec;14(6):540-5 [1798888.001]
  • [Cites] Neuropediatrics. 1992 Feb;23(1):39-45 [1565216.001]
  • [Cites] J Epidemiol Community Health. 1992 Apr;46(2):92-7 [1583440.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Sleep. 1992 Aug;15(4):376-81 [1519015.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):547-56 [9053476.001]
  • [Cites] J Pain Symptom Manage. 1997 Feb;13(2):63-74 [9095563.001]
  • [Cites] Support Care Cancer. 1998 Mar;6(2):101-8 [9540167.001]
  • [Cites] J Psychosom Res. 1998 Jul;45(1):5-13 [9720850.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):253-61 [10458240.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5501-10 [16110010.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6587-95 [16170166.001]
  • [Cites] Ann Intern Med. 2005 Nov 1;143(9):639-47 [16263886.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • (PMID = 18274275.001).
  • [ISSN] 0161-8105
  • [Journal-full-title] Sleep
  • [ISO-abbreviation] Sleep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U24 CA 55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2225565
  •  go-up   go-down


62. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Koenig KL, Kolonel LN, Laden F, McCullough ML, Parisi D, Purdue MP, Shu XO, Snyder K, Stolzenberg-Solomon RZ, Tworoger SS, Varanasi A, Virtamo J, Wilkens LR, Xiang YB, Yu K, Zeleniuch-Jacquotte A, Zheng W, Abnet CC, Albanes D, Bertrand K, Weinstein SJ: Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol; 2010 Jul 1;172(1):10-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases (total n = 5,491) included incident primary endometrial (n = 830), kidney (n = 775), ovarian (n = 516), pancreatic (n = 952), and upper gastrointestinal tract (n = 1,065) cancers and non-Hodgkin lymphoma (n = 1,353) diagnosed in the participating cohorts.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):21-35 [20562191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1427-37 [16896028.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10213-9 [17047087.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):783-8 [17416771.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):123-8 [17551495.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):236-42 [17696738.001]
  • [Cites] Nutr Rev. 2007 Aug;65(8 Pt 2):S71-4 [17867373.001]
  • [Cites] Med Sci Sports Exerc. 2007 Oct;39(10):1700-7 [17909395.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Int J Biometeorol. 2000 Nov;44(4):186-9 [11131290.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1867-75 [11920550.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] Cancer. 2002 May 1;94(9):2490-501 [12015775.001]
  • [Cites] Am J Clin Nutr. 2002 Jul;76(1):3-4 [12081814.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):255-65 [15090720.001]
  • [Cites] Clin Chem. 1981 May;27(5):773-4 [7226510.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):373-8 [2839537.001]
  • [Cites] Lancet. 1991 Aug 24;338(8765):464-8 [1678444.001]
  • [Cites] N Engl J Med. 1994 Apr 14;330(15):1029-35 [8127329.001]
  • [Cites] Ann Epidemiol. 1994 Jan;4(1):1-10 [8205268.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):190-7 [7707406.001]
  • [Cites] Int J Epidemiol. 1994 Dec;23(6):1133-6 [7721513.001]
  • [Cites] J Clin Epidemiol. 1995 Aug;48(8):1077-85 [7775995.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1297-302 [7658481.001]
  • [Cites] JAMA. 1999 Apr 28;281(16):1505-11 [10227320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):525-32 [10385143.001]
  • [Cites] Health Phys. 2004 Nov;87(5):532-8 [15551791.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):258-61 [15613728.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1123-31 [16236996.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-97-101 [16315387.001]
  • [Cites] Mutat Res. 2005 Dec 30;592(1-2):147-54 [16054167.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):977-85 [16341085.001]
  • [Cites] Am J Public Health. 2006 Feb;96(2):252-61 [16380576.001]
  • [Cites] Prev Med. 2007 Nov;45(5):327-31 [17395256.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2237-46 [18006912.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S182-94 [18844847.001]
  • [Cites] Am J Clin Nutr. 2008 Dec;88(6):1519-27 [19064511.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] Clin Biochem. 2009 Oct;42(15):1549-56 [19631201.001]
  • [Cites] Cancer Causes Control. 2010 Apr;21(4):643-8 [20020320.001]
  • [Cites] Am J Epidemiol. 2006 Jun 1;163(11):1053-64 [16624970.001]
  • (PMID = 20562188.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CP / N02-CP-11010-66; United States / CCR NIH HHS / RC / N01-RC-45035; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CA / N01 CN25514; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / PC / N01-PC35137; United States / NCI NIH HHS / CA / R37 CA70867; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / R37 CA070867; United States / NCI NIH HHS / CA / N01 CN25524; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / N01 CN25513; United States / NCI NIH HHS / CA / R01 CA49449; United States / NCI NIH HHS / CA / P01 CA33619; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R37 CA54281; United States / CCR NIH HHS / RC / N01-RC-37004; United States / NCI NIH HHS / CA / N01 CN75022; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / N01 CN25512; United States / NCI NIH HHS / CN / N01-CN-45165; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / P01 CA033619; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / N01 CN25518; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CA / R01 CA82729; United States / NCI NIH HHS / CA / N01 CN25516; United States / NCI NIH HHS / CA / N01 CN25511; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CA / R01 CA105069; United States / NCI NIH HHS / CA / N01 CN25476; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01 CN045165; United States / NCI NIH HHS / CP / N02CP11010; United States / NCI NIH HHS / CA / N01 CN25522; United States / NCI NIH HHS / CA / N01 CN25515; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NIA NIH HHS / AG / U01 AG018033; United States / NCI NIH HHS / CN / N01-CN-25522; United States / NCI NIH HHS / CA / K07 CA73790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2892539
  •  go-up   go-down


63. Proca DM, De Renne L, Marsh WL Jr, Keyhani-Rofagha S: Anaplastic large cell lymphoma in a human immunodeficiency virus-positive patient with cytologic findings in bladder wash: a case report. Acta Cytol; 2008 Jan-Feb;52(1):83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma in a human immunodeficiency virus-positive patient with cytologic findings in bladder wash: a case report.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) (Ki-1/CD-30 positive) is an uncommon lymphoproliferative disorder that may be of T cell or null cell type.
  • The ALCL was CD30+ and null cell type, with negative CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD45, CD79a, ALK-1, granzyme B, cytokeratin (AE1/AE3), placental alkaline phosphatase (PLAP) and S-100.
  • CONCLUSION: This is a rare occurrence of ALCL (CD 30 positive, null cell type) in the urinary bladder in an HIV+ patient.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis. Urinary Bladder / pathology
  • [MeSH-minor] Adult. Humans. Male


64. Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC: A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia; 2009 May;23(5):912-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma but is associated with tumor necrosis factor-alpha (TNF-alpha) release that can cause CLL proliferation and inhibit apoptosis.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Haematologica. 2006 Jun;91(6 Suppl):ECR23 [16785126.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68 [17707833.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1962-3 [10561242.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] Blood Cells Mol Dis. 2000 Apr;26(2):133-43 [10753604.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):203-10 [10962531.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Sep;50(3):237-42 [12203106.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):36-8 [12517774.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1259-63 [7999409.001]
  • [Cites] Blood. 1995 Jan 15;85(2):307-18 [7811987.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):5038-45 [7594512.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Immunol Cell Biol. 1997 Apr;75(2):127-35 [9107564.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4342-9 [9596683.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Immunol Methods. 2005 Sep;304(1-2):88-99 [16109421.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):437-43 [16344317.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):266-72 [16755224.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • (PMID = 19225537.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / P01 CA9542
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; OP401G7OJC / Etanercept; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS79899; NLM/ PMC4099250
  •  go-up   go-down


65. Pilichowska ME, Smouse JH, Dorfman DM: Concurrent herpes simplex viral lymphadenitis and mantle cell lymphoma: a case report and review of the literature. Arch Pathol Lab Med; 2006 Apr;130(4):536-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent herpes simplex viral lymphadenitis and mantle cell lymphoma: a case report and review of the literature.
  • We report a case of localized herpes simplex virus lymphadenitis in a patient with mantle cell lymphoma (MCL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Herpes Simplex / pathology. Lymphadenitis / pathology. Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antiviral Agents / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Ganciclovir / therapeutic use. Humans. Neoplasm Staging. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594747.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P9G3CKZ4P5 / Ganciclovir; CVAD protocol
  •  go-up   go-down


66. Xie XS, Wan DM, Sun H: [Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation for 8 patients with leukemia and review of the literature]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):636-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation for 8 patients with leukemia and review of the literature].
  • [MeSH-major] HLA Antigens / immunology. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Haplotypes. Histocompatibility Testing. Humans. Male. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122422.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


67. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM: Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol; 2006 Feb 20;24(6):983-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease.
  • PATIENTS AND METHODS: Specimens were collected from the peripheral blood of individuals diagnosed with B-cell chronic lymphocytic leukemia (B-CLL; n = 70) or from age- and sex-matched patients seen at the same institution (n = 41).
  • [MeSH-major] Biomarkers, Tumor / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Lymphoma, B-Cell / blood. Membrane Proteins / blood
  • [MeSH-minor] Adult. Aged. B-Cell Activating Factor. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. HL-60 Cells. Humans. Male. Middle Aged. Polymorphism, Restriction Fragment Length. Promoter Regions, Genetic. Sequence Analysis, DNA. Tumor Necrosis Factor-alpha / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432079.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / TNFSF13B protein, human; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


68. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ; 2009 Dec 08;339:b4606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.
  • OBJECTIVES: To assess the incidence of and risks for congestive heart failure, myocardial infarction, pericardial disease, and valvular abnormalities among adult survivors of childhood and adolescent cancers.
  • PARTICIPANTS: 14,358 five year survivors of cancer diagnosed under the age of 21 with leukaemia, brain cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, neuroblastoma, soft tissue sarcoma, or bone cancer between 1970 and 1986.
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Case-Control Studies. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. United States. Young Adult

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Saf. 2000 Apr;22(4):263-302 [10789823.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):31-7 [3581032.001]
  • [Cites] Stat Med. 1990 May;9(5):505-14 [2190287.001]
  • [Cites] Am J Cardiol. 1975 Feb;35(2):216-20 [1119380.001]
  • [Cites] Chest. 1991 Mar;99(3):538-45 [1995208.001]
  • [Cites] Am J Hematol. 1991 Mar;36(3):217-8 [1705095.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] JAMA. 1991 Sep 25;266(12):1672-7 [1886191.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):182-8 [8004574.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):328-31 [8636739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Nov 1;36(4):881-9 [8960517.001]
  • [Cites] Am J Med Sci. 1997 Dec;314(6):399-400 [9413345.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):35-42 [10386715.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jun 15;44(7):600-6 [15856486.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):153-9 [15900998.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):173-85 [15896910.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):324-32 [15714447.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7685-96 [16234530.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] J Clin Epidemiol. 2006 Aug;59(8):862-7 [16828682.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3191-8 [16987655.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1878-86 [17119114.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3635-43 [17704413.001]
  • [Cites] Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120 [18512336.001]
  • [Cites] Curr Treat Options Oncol. 2008 Feb;9(1):51-66 [18363110.001]
  • [Cites] BMC Cancer. 2008;8:141 [18492236.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2319-27 [19364957.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(11):1191-6 [10849532.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):429-47 [11139373.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] Arch Intern Med. 2001 Jan 22;161(2):277-84 [11176744.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] JAMA. 2002 Apr 10;287(14):1832-9 [11939869.001]
  • [Cites] Med Pediatr Oncol. 2002 Aug;39(2):86-92 [12116055.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] J Am Coll Cardiol. 2003 Aug 20;42(4):743-9 [12932613.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Am J Epidemiol. 2003 Dec 1;158(11):1108-13 [14630607.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):769-73 [14990630.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):37-44 [15162142.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [CommentIn] BMJ. 2009;339:b4691 [19996460.001]
  • (PMID = 19996459.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24 CA 55727; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / 1K12RR023247; United States / NCI NIH HHS / CA / U24 CA055727-17; United States / NCRR NIH HHS / RR / K12 RR023247-05; United States / NCRR NIH HHS / RR / K12 RR023247
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3266843
  •  go-up   go-down


69. Mani D, Dorer RK, Aboulafia DM: Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma; 2009 Aug;9(4):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
  • Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
  • The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 11 / genetics. Cytogenetic Analysis. Fatal Outcome. Follow-Up Studies. Histone-Lysine N-Methyltransferase. Humans. Male. Myeloid-Lymphoid Leukemia Protein / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717383.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


70. Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y: Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol; 2009 May 10;27(14):2374-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk factors for PM included attained age, exposure to increasing doses of radiation to the ovaries, increasing alkylating agent score, and a diagnosis of Hodgkin's lymphoma.


71. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol; 2009 Mar 10;27(8):1209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of deferred initial therapy in mantle-cell lymphoma.
  • PURPOSE: Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are commonly treated immediately at diagnosis.
  • Prognostic factors in assessable patients included advanced stage (III/IV) in 75%, elevated lactate dehydrogenase in 25%, and intermediate- or high-risk Mantle Cell International Prognostic Index in 54%.
  • [MeSH-major] Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prognosis. Treatment Outcome. Vincristine / administration & dosage


72. Fon A, Mileshkin L, Slavin J, Twomey H, James P, Thomas DM: Synchronous diagnosis of Hodgkin lymphoma and osteosarcoma. Intern Med J; 2007 Oct;37(10):731-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous diagnosis of Hodgkin lymphoma and osteosarcoma.
  • [MeSH-minor] Adult. Humans. Male


73. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol; 2005 Jul 1;23(19):4390-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
  • PURPOSE: This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma.
  • PATIENTS AND METHODS: Patients had follicular lymphoma that had relapsed or failed to respond to primary therapy; the majority (90%) presented with stage III or IV disease.
  • CONCLUSION: The favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD80 / immunology. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Infection / complications. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994148.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD80; 0 / Antineoplastic Agents; 357613-77-5 / galiximab
  •  go-up   go-down


74. Balasubramaniam R, Goradia A, Turner LN, Stoopler ET, Alawi F, Frank DM, Greenberg MS: Burkitt lymphoma of the oral cavity: an atypical presentation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Feb;107(2):240-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma of the oral cavity: an atypical presentation.
  • Burkitt lymphoma (BL) is an aggressive form of non-Hodgkin B-cell lymphoma with 3 variants: endemic, sporadic, and immunodeficiency-associated types.
  • An incisional biopsy revealed a diffuse proliferation of intermediate- to large-sized lymphocytes with multiple small peripheral nucleoli, scant cytoplasm, and nuclear pleomorphism.
  • [MeSH-major] Burkitt Lymphoma / pathology. Gingival Neoplasms / pathology. Mandibular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Infusions, Intralesional. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138642.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


75. Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA: A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Dec 1;12(23):7046-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
  • PURPOSE: The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Interleukin-2 / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD / genetics. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Injections, Intravenous. Injections, Subcutaneous. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Polymorphism, Genetic / genetics. Receptors, IgG / genetics. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145827.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K01 CA95426-01A1; United States / NCI NIH HHS / CA / K08 CA93518-01; United States / NCI NIH HHS / CA / K23 CA102155
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / FCGR3A protein, human; 0 / Fc gamma receptor IIA; 0 / Interleukin-2; 0 / Receptors, IgG; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


76. Plaisier MB, Sie-Go DM, Berendschot TT, Petersen EJ, Mourits MP: Ocular adnexal lymphoma classified using the WHO classification: not only histology and stage, but also gender is a predictor of outcome. Orbit; 2007 Jun;26(2):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular adnexal lymphoma classified using the WHO classification: not only histology and stage, but also gender is a predictor of outcome.
  • MALT lymphoma appears to be the most frequent OAL.
  • Of those with primary OAL, 27 had MALT, eight diffuse large B-cell, six mantle cell and eight follicular cell lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification. Orbital Neoplasms / classification
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Eyelids / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care). Predictive Value of Tests. Prognosis. Proportional Hazards Models. Sex Factors. Survival Analysis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613853.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Chawla S, Zhang Y, Wang S, Chaudhary S, Chou C, O'Rourke DM, Vossough A, Melhem ER, Poptani H: Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr; 2010 Nov-Dec;34(6):836-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Contrast Media. Creatine / metabolism. Diagnosis, Differential. Female. Gadolinium DTPA. Glutamic Acid / metabolism. Glutamine / metabolism. Humans. Inositol / metabolism. Lipid Metabolism. Magnetic Resonance Spectroscopy / methods. Male. Middle Aged. ROC Curve. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084897.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0RH81L854J / Glutamine; 30KYC7MIAI / Aspartic Acid; 3KX376GY7L / Glutamic Acid; 4L6452S749 / Inositol; 84F6U3J2R6 / gadodiamide; 997-55-7 / N-acetylaspartate; K2I13DR72L / Gadolinium DTPA; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


78. Seidler AM, Gottlieb AB: Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol; 2008 Nov;59(5):872-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Drugs have occasionally been implicated in dermatomyositis (DM) onset.
  • OBJECTIVE: We sought to review case reports of drug-induced DM.
  • Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis).
  • Of the sample, 84.3% had improvement of DM after discontinuation of the drug.
  • [MeSH-minor] Adult. Aged. Antibodies, Antinuclear / analysis. Autoimmune Diseases / drug therapy. Cyclophosphamide / adverse effects. Etoposide / adverse effects. Female. Humans. Hydroxyurea / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625537.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 27
  •  go-up   go-down


79. de Ru JA, van Leeuwen MS, van Benthem PP, Velthuis BK, Sie-Go DM, Hordijk GJ: Do magnetic resonance imaging and ultrasound add anything to the preoperative workup of parotid gland tumors? J Oral Maxillofac Surg; 2007 May;65(5):945-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenolymphoma / pathology. Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle / methods. Lymphoma, B-Cell, Marginal Zone / pathology. Parotid Diseases / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Facial Nerve / anatomy & histology. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging / methods. Parotid Gland / anatomy & histology. Parotid Gland / innervation. Physical Examination. Reference Standards. Single-Blind Method

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448846.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Xie XS, Wan DM, Sun H, Sun L, Liu LX, Jiang ZX: [Peripheral blood stem cell transplantation for 53 patients with malignant hematologic diseases]. Ai Zheng; 2007 Apr;26(4):403-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peripheral blood stem cell transplantation for 53 patients with malignant hematologic diseases].
  • BACKGROUND & OBJECTIVE: Hematopoietic stem cell transplantation could improve the prognosis of malignant hematologic diseases.
  • Peripheral blood stem cell transplantation (PBSCT) has been gradually used as an alternative to bone marrow transplantation (BMT).
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cyclosporine / administration & dosage. Cyclosporine / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Male. Methotrexate / administration & dosage. Middle Aged. Mycophenolic Acid / administration & dosage. Mycophenolic Acid / analogs & derivatives. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430661.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


81. Dulai MS, Park CY, Howell WD, Smyth LT, Desai M, Carter DM, Vogel H: CNS T-cell lymphoma: an under-recognized entity? Acta Neuropathol; 2008 Mar;115(3):345-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS T-cell lymphoma: an under-recognized entity?
  • The incidence of CNS lymphoma has increased significantly in the past 30 years, primarily in the elderly and immunocompromised.
  • While T-cell lymphomas comprise 15-20% of systemic lymphomas, they comprise less than 4% of primary CNS lymphomas, suggesting that they may be under-recognized compared to their systemic counterparts.
  • To investigate this, we studied brain biopsies from three patients who were diagnosed with T-cell lymphoma confined to the brain.
  • We compared these to biopsies from three patients who had reactive lymphoid infiltrates and who had clinical signs/symptoms and radiographic findings that were indistinguishable from the lymphoma group.
  • Biopsies from both the lymphoma group and reactive group showed considerable cytomorphologic heterogeneity.
  • Although one lymphoma case contained large atypical cells, the other two contained small, mature lymphocytes within a heterogeneous infiltrate of neoplastic and reactive inflammatory cells.
  • Surface marker aberrancies were present in two lymphoma cases, but this alone could not reliably diagnose T-cell lymphoma.
  • The proliferation index was not useful for differentiating lymphoma from reactive infiltrates.
  • In five of the six cases the diagnosis was most influenced by clonality studies for T-cell receptor-gamma gene rearrangements.
  • We conclude that because of the high degree of overlap in cytomorphologic and immunophenotypic features between T-cell lymphoma and reactive infiltrates, T-cell lymphoma may not be recognized unless studies for T-cell receptor gene rearrangements are performed for CNS lesions composed of a polymorphous but predominantly T-cell infiltrate.
  • [MeSH-major] Brain Diseases / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunohistochemistry. In Situ Hybridization. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196250.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Matos DM, Rizzatti EG, Garcia AB, Gallo DA, Falcão RP: Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase. Braz J Med Biol Res; 2006 Oct;39(10):1349-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase.
  • We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and before the beginning of any therapy.
  • The diagnosis of B-cell non-Hodgkin's lymphomas was based on cytological, histological, immunophenotypic, and molecular biology methods.
  • Comparison of chronic lymphocytic leukemia and mantle-cell lymphoma showed that the former presented a higher expression of CD11c and CD49c, and a lower expression of CD11b and CD49d adhesion molecules.
  • Comparison of chronic lymphocytic leukemia and marginal B-cell lymphoma showed that the former presented a higher expression of CD49c and a lower expression of CD11a, CD11b, CD18, CD49d, CD29, and CD54.
  • Finally, comparison of mantle-cell lymphoma and marginal B-cell lymphoma showed that marginal B-cell lymphoma had a higher expression of CD11a, CD11c, CD18, CD29, and CD54.
  • Thus, the CD49c/CD49d pair consistently demonstrated a distinct pattern of expression in chronic lymphocytic leukemia compared with mantle-cell lymphoma and marginal B-cell lymphoma, which could be helpful for the differential diagnosis.

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053842.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules
  •  go-up   go-down


83. Gonçalves TL, Benvegnú DM, Bonfanti G: Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid Med Cell Longev; 2009 Apr-Jun;2(2):82-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation.
  • Successful hematopoietic stem cell transplantation (HSCT), both autologous and allogeneic, requires a rapid and durable engraftment, with neutrophil (>500/microL) and platelet (>20,000/microL) reconstitution.
  • Factors influencing engraftment after autologous or allogeneic HSCT were investigated in 65 patients: 25 autologous peripheral stem cell transplantation (PBSCT) and 40 allogeneic bone marrow transplantation (BMT) patients.
  • The type of disease also affected engraftment, where multiple myeloma (MM) and lymphoma showed faster engraftment when compared with leukemia, syndrome myelodysplastic (SMD) and aplastic anemia (AA) and MM presented the best overall survival (OS) in a period of 12 months.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Anemia, Aplastic / mortality. Anemia, Aplastic / therapy. Bone Marrow Transplantation. Female. Humans. Leukemia / mortality. Leukemia / therapy. Lymphoma / mortality. Lymphoma / therapy. Male. Middle Aged. Multiple Myeloma / mortality. Multiple Myeloma / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Peripheral Blood Stem Cell Transplantation. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jun 15;95(12):3702-9 [10845900.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1655-8 [7534140.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3380-9 [11369627.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):698-700 [11553000.001]
  • [Cites] Br J Nutr. 2002 Jan;87 Suppl 1:S9-15 [11895159.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(10):825-32 [12058232.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1620-9 [12393457.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1328-35 [7538556.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2794-800 [8839878.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):600-7 [9103126.001]
  • [Cites] Baillieres Clin Haematol. 1997 Jun;10(2):319-36 [9376667.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] Exp Hematol. 1998 May;26(5):409-14 [9590657.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):939-43 [15489866.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Sep;11(9):688-97 [16125639.001]
  • [Cites] Br J Haematol. 2006 May;133(3):305-14 [16643433.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1450-6 [17355954.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):165-70 [18162238.001]
  • [Cites] Pediatr Transplant. 2008 Feb;12(1):14-9 [18086256.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Mar;14(3):301-8 [18275896.001]
  • [Cites] Transfus Apher Sci. 2003 Aug;29(1):53-9 [12877895.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L706-14 [15020295.001]
  • [Cites] N Engl J Med. 1994 Mar 24;330(12):827-38 [8114836.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):750-8 [10984562.001]
  • (PMID = 20357929.001).
  • [ISSN] 1942-0994
  • [Journal-full-title] Oxidative medicine and cellular longevity
  • [ISO-abbreviation] Oxid Med Cell Longev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2763249
  • [Keywords] NOTNLM ; bone marrow transplantation / conditioning regimen / engraftment / hematopoietic stem cell transplantation / peripheral blood stem cell transplantation
  •  go-up   go-down


84. Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J: Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res; 2005 Jul 15;11(14):5215-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
  • EXPERIMENTAL DESIGN: Cohorts of three to six patients with B-cell lymphoma received 185 MBq/m2 [90Y]epratuzumab with unconjugated epratuzumab (total protein dose 1.5 mg/kg) once weekly for two to four infusions, with [(111)In]epratuzumab coadministered at first infusion for scintigraphic imaging and dosimetry.
  • Of 13 patients with tumor cell CD22 expression determined by flow cytometry, seven of eight with strongly positive results had objective responses, versus one of five with negative or weakly positive results (P = 0.032).
  • CONCLUSIONS: Radioimmunotherapy with weekly 185 MBq/m2 [90Y]epratuzumab achieved a high objective response rate (62%) across lymphoma subtypes, including durable CRs.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. Cell Adhesion Molecules / biosynthesis. Disease-Free Survival. Female. Gene Expression Profiling. Humans. Infusions, Intravenous. Lectins / biosynthesis. Male. Middle Aged. Radioimmunotherapy. Sialic Acid Binding Ig-like Lectin 2. Treatment Outcome. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033839.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Yttrium Radioisotopes; 0 / epratuzumab
  •  go-up   go-down


85. Edge JC, Outland JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol; 2006 Jan;142(1):65-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dermatomyositis (DM) is a multisystem idiopathic inflammatory disorder that most commonly affects the muscles and skin.
  • OBSERVATIONS: We sought to evaluate the effectiveness of oral mycophenolate mofetil in patients with cutaneous lesions of DM recalcitrant to other therapies through an open-label retrospective medical chart review of patients in a university-affiliated private practice setting.
  • Twelve patients with DM who had skin lesions recalcitrant to traditional therapies or who developed toxic effects from traditional therapies began mycophenolate mofetil treatment at doses ranging from 500 mg to 1 g twice a day.
  • Most patients tolerated mycophenolate mofetil treatment without problem; however, 1 patient developed a B-cell lymphoma of the central nervous system, and another developed abnormal levels of hepatic enzymes along with urinary symptoms.
  • CONCLUSION: Mycophenolate mofetil may be an effective corticosteroid-sparing therapy for the treatment of some patients with DM.
  • [MeSH-minor] Adult. Disease Progression. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Paraneoplastic Syndromes / drug therapy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Dermatomyositis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415388.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 0 / Prodrugs; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


86. Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP: Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol; 2008 Jul;19(7):1327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
  • BACKGROUND: Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3-4 years.
  • Single-center studies with R-Hyper-CVAD and/or autologous stem-cell transplant (ASCT) have produced 3-year OS rates >80%, prompting many to adopt their use.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349031.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


87. Ellison DA, Parham DM, Sawyer JR: Cytogenetic findings in pediatric T-lymphoblastic lymphomas: one institution's experience and a review of the literature. Pediatr Dev Pathol; 2005 Sep-Oct;8(5):550-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytogenetic analyses of lymphomas commonly reveal nonrandom chromosomal abnormalities, but there are relatively few reports in childhood lymphoblastic lymphoma (LL).
  • Six children (2 to 20 years old) had LL that presented as mediastinal or cervical masses and had a T-cell immunophenotype and clonal abnormalities.
  • Eleven chromosome breakpoints in 6 of our patients (7q11, 12p13, 16p13, 18q21, 9q11, 2p11, 2q13, 7q32, and 7q23) have been reported in other patients with acute lymphoblastic leukemia or LL and involved regions containing TEL, ABL, E2A, MLL, and T-cell receptor-alpha genes.
  • A review of the cytogenetic findings of these and other cases of LL reveals that clonal aberrations are common and most frequently involve T-cell receptor gene regions.
  • [MeSH-major] Chromosome Aberrations. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Karyotyping. Male. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211447.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Purdue MP, Freedman DM, Gapstur SM, Helzlsouer KJ, Laden F, Lim U, Maskarinec G, Rothman N, Shu XO, Stevens VL, Zeleniuch-Jacquotte A, Albanes D, Bertrand K, Weinstein SJ, Yu K, Irish L, Horst RL, Hoffman-Bolton J, Giovannucci EL, Kolonel LN, Snyder K, Willett W, Arslan AA, Hayes RB, Zheng W, Xiang YB, Hartge P: Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol; 2010 Jul 1;172(1):58-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
  • Case-control studies generally suggesting an inverse association between sun exposure and non-Hodgkin lymphoma (NHL) have led to speculation that vitamin D may protect against lymphomagenesis.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):132-9 [16595142.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):587-94 [15840881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):396-400 [17337644.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2445-51 [17311289.001]
  • [Cites] Am J Epidemiol. 2007 Jun 1;165(11):1255-64 [17327216.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1634-47 [17641030.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1031-7 [17653828.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):989-99 [17653830.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):979-86 [19035445.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] Clin Biochem. 2009 Oct;42(15):1549-56 [19631201.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):10-20 [20562188.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):21-35 [20562191.001]
  • [Cites] Health Place. 1998 Dec;4(4):355-64 [10670982.001]
  • [Cites] Immunol Cell Biol. 2001 Dec;79(6):547-68 [11903614.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] Recent Results Cancer Res. 2003;164:371-7 [12899536.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):59-64 [14744734.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):255-65 [15090720.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • [Cites] Science. 1983 Sep 16;221(4616):1181-3 [6310748.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Dec;57(6):1308-10 [6313738.001]
  • [Cites] Br J Cancer. 1991 Mar;63(3):463-5 [2003990.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):668-72 [8398690.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):298-300 [8614009.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):945-50 [8611412.001]
  • [Cites] BMJ. 1996 May 4;312(7039):1128-31 [8620128.001]
  • [Cites] Photochem Photobiol. 1996 Aug;64(2):254-8 [8760564.001]
  • [Cites] BMJ. 1997 May 17;314(7092):1451-5 [9167561.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):995-1009 [10354063.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • (PMID = 20562184.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CP / N02-CP-11010-66; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CA / N01 CN25514; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / PC / N01-PC35137; United States / NCI NIH HHS / CA / R37 CA70867; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / R37 CA070867; United States / NCI NIH HHS / CA / N01 CN25524; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / N01 CN25513; United States / NCI NIH HHS / CA / R01 CA49449; United States / NCI NIH HHS / CA / P01 CA33619; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R37 CA54281; United States / NCI NIH HHS / CA / N01 CN75022; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / N01 CN25512; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / P01 CA033619; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / N01 CN25518; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CA / N01 CN25516; United States / NCI NIH HHS / CA / N01 CN25511; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CA / R01 CA105069; United States / NCI NIH HHS / CA / N01 CN25476; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01 CN045165; United States / NCI NIH HHS / CP / N02CP11010; United States / NCI NIH HHS / CA / N01 CN25522; United States / NCI NIH HHS / CA / N01 CN25515; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NIA NIH HHS / AG / U01 AG018033; United States / NCI NIH HHS / CN / N01-CN-25522; United States / NCI NIH HHS / CA / K07 CA73790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2892540
  •  go-up   go-down


89. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM: High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol; 2010 Aug 10;28(23):3709-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
  • PURPOSE: Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: A multicenter trial evaluated two or three weekly infusions of yttrium-90 ((90)Y) epratuzumab tetraxetan (humanized anti-CD22 antibody) in 64 patients with relapsed/refractory NHL, including 17 patients who underwent prior autologous stem-cell transplantation (ASCT).
  • For patients with follicular lymphoma (FL), OR rates and median PFS increased with total (90)Y-dose, reaching 100% (CR/CRu, 92%) and 24.6 months, respectively, at the highest dose levels (> 30 mCi/m(2) total (90)Y-dose [1,110 MBq/m(2)]).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; 0 / epratuzumab
  •  go-up   go-down


90. Carrera E, Lobrinus JA, Spertini O, Gherardi RK, Kuntzer T: Dermatomyositis, lobar panniculitis and inflammatory myopathy with abundant macrophages. Neuromuscul Disord; 2006 Jul;16(7):468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatomyositis (DM) is a rare treatable muscle disorder with a reported favorable outcome in most patients.
  • A localized skin/muscle involvement in a DM patient raises questions of definition and causes such as lymphoma, or relapse.
  • We describe here a young treated DM patient who presented a focal biopsy-proven destructive myositis and dermatitis restricted to the left thigh 15 months after the onset of a treated dermatomyositis.
  • We conclude that this focal complication suggests a continuum between dermatomyositis, CHP, and IMAM, the three syndromes where T-cell activation plays an important role.
  • [MeSH-minor] Adult. Biopsy. Humans. Magnetic Resonance Imaging. Male. Muscle, Skeletal / pathology

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Panniculitis.
  • MedlinePlus Health Information. consumer health - Myositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809038.001).
  • [ISSN] 0960-8966
  • [Journal-full-title] Neuromuscular disorders : NMD
  • [ISO-abbreviation] Neuromuscul. Disord.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM: Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant; 2009 May;15(5):547-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
  • Diagnoses included diffuse large B-cell lymphoma (n = 18), Burkitt's lymphoma (n = 3), transformed B cell lymphoma (n = 5), mantle cell lymphoma (n = 11), and peripheral T cell lymphoma (n = 9).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Disease Progression. Follow-Up Studies. Graft vs Host Disease. Humans. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult


92. Schreeder DM, Pan J, Li FJ, Vivier E, Davis RS: FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia. Eur J Immunol; 2008 Nov;38(11):3159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia.
  • Fc receptor-like 6 (FCRL6), the most recently characterized member of the FCRL family, is a cell surface glycoprotein with tyrosine-based regulatory potential.
  • An extensive survey of human hematopoietic tissues disclosed that FCRL6 expression by NK- and T-cell subpopulations increases as a function of differentiation and is remarkably restricted to mature lymphocytes with cytotoxic capability.
  • In particular, FCRL6 distinguishes perforin-expressing CD56dim NK cells, Vdelta1+ and Vdelta2+ gammadelta T cells, effector and effector memory CD8+ T cells, and rare cytotoxic CD4+ T cells in adult tissues.
  • Analysis of this receptor in B-cell chronic lymphocytic leukemia (CLL) was also performed.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2006 Dec 25;203(13):2865-77 [17158960.001]
  • [Cites] Eur J Immunol. 2006 Dec;36(12):3198-206 [17109473.001]
  • [Cites] Blood. 2007 May 1;109(9):3786-93 [17213291.001]
  • [Cites] Blood. 2008 Jul 1;112(1):179-87 [18314442.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Science. 2000 Oct 6;290(5489):84-9 [11021804.001]
  • [Cites] Springer Semin Immunopathol. 2000;22(3):191-217 [11116953.001]
  • [Cites] Immunity. 2001 Mar;14(3):277-89 [11290337.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9772-7 [11493702.001]
  • [Cites] Trends Immunol. 2001 Nov;22(11):633-40 [11698225.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5954-8 [12023402.001]
  • [Cites] Immunol Rev. 2002 Dec;190:123-36 [12493010.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1063-70 [12393705.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):383-9 [12688308.001]
  • [Cites] Nat Rev Immunol. 2003 May;3(5):413-25 [12766763.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13489-94 [14597715.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1455-62 [14734722.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):999-1010 [15048710.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1801-7 [15178578.001]
  • [Cites] J Immunol. 1982 Nov;129(5):2001-3 [6181153.001]
  • [Cites] J Immunol. 1982 Nov;129(5):2305-12 [6214590.001]
  • [Cites] J Exp Med. 1993 Dec 1;178(6):2023-33 [7504054.001]
  • [Cites] J Immunol. 1994 Nov 1;153(9):4281-90 [7930628.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Immunol Today. 1997 Jun;18(6):286-91 [9190115.001]
  • [Cites] Immunity. 1997 Aug;7(2):283-90 [9285412.001]
  • [Cites] Science. 1998 Mar 13;279(5357):1737-40 [9497295.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1121-6 [15479727.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):312-9 [15886123.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1797-805 [15965501.001]
  • [Cites] Mol Biol (Mosk). 2005 Sep-Oct;39(5):776-85 [16240711.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;298:1-21 [16329183.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):1033-43 [16606675.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3824-33 [16902150.001]
  • [Cites] Annu Rev Immunol. 2007;25:525-60 [17201682.001]
  • (PMID = 18991291.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI067467; United States / NIAID NIH HHS / AI / AI007051; United States / NIAID NIH HHS / AI / T32 AI007051; United States / NIAID NIH HHS / AI / AI55638; United States / NIAID NIH HHS / AI / T32 AI007051-23; United States / NIAID NIH HHS / AI / AI055638-03; United States / NIAID NIH HHS / AI / AI007051-23; United States / NIAID NIH HHS / AI / R01 AI067467-02; United States / NIAID NIH HHS / AI / K08 AI055638; United States / Howard Hughes Medical Institute / / ; United States / NIAID NIH HHS / AI / K08 AI055638-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / FCRL6 protein, human; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS137216; NLM/ PMC2742621
  •  go-up   go-down


93. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol; 2009 Jul 10;27(20):3354-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
  • RESULTS: Diffuse large B-cell lymphoma (n = 43), polymorphic PTLD (n = 10), Hodgkin's lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tissue lymphoma (n = 3) were all over-represented in the SOT population compared with a population sample from the Surveillance, Epidemiology, and End Results (SEER) database; follicular lymphoma (n = 0) was underrepresented.
  • Extralymphatic disease (79%), poor performance status (68%), elevated lactate dehydrogenase (LDH; 71%), and advanced stage (68%) disease were all common at the time of lymphoma diagnosis.
  • Follicular lymphoma is unusual.
  • [MeSH-major] Lymphoma / etiology. Lymphoproliferative Disorders / etiology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / metabolism. Humans. Immunohistochemistry. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. In Situ Hybridization. Kaplan-Meier Estimate. Male. Michigan. Middle Aged. RNA, Viral / genetics. Risk Factors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use. Treatment Outcome. Viral Matrix Proteins / metabolism


94. Combs S, Neil N, Aboulafia DM: Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study. Oncologist; 2006 Jun;11(6):666-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study.
  • PURPOSE: To evaluate in a pilot study the safety and efficacy of liposomal doxorubicin, cyclophosphamide, and etoposide (LACE) when combined with antiretroviral therapy (ART) in patients with AIDS-related lymphoma (ARL).
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Carriers. Etoposide / administration & dosage. Female. Humans. Liposomes. Male. Middle Aged. Pilot Projects. Survival Rate. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794245.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Drug Carriers; 0 / Liposomes; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; ACE protocol 1
  •  go-up   go-down


95. Dunford LM, Roy DM, Hahn TE, Padmanabhan S, Segal BH, Almyroudis N, McCarthy PL Jr, Battiwalla M: Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant; 2006 Feb;12(2):241-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation.
  • [MeSH-major] Anti-Infective Agents / adverse effects. Dapsone / adverse effects. Hematopoietic Stem Cell Transplantation. Methemoglobinemia / chemically induced. Pneumocystis Infections / prevention & control
  • [MeSH-minor] Adult. Anemia, Aplastic / complications. Anemia, Aplastic / therapy. Female. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Pneumocystis Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAPSONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Biol Blood Marrow Transplant. 2005 Jul;11(7):521-9 [15983552.001]
  • (PMID = 16443522.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8W5C518302 / Dapsone
  •  go-up   go-down


96. Benson DM Jr, Smith MK, Krugh D, Devine SM: Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab. Bone Marrow Transplant; 2008 Mar;41(6):595-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Graft vs Host Disease / complications. Graft vs Host Disease / drug therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Red-Cell Aplasia, Pure / etiology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Hemoglobins / analysis. Humans. Lymphoma, Large B-Cell, Diffuse / therapy. Remission Induction. Reticulocyte Count. Rituximab. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Bone Marrow Transplant. 2007 Aug;40(3):273-7 [17549053.001]
  • (PMID = 18037934.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Hemoglobins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


97. Mani D, Guinee DG Jr, Aboulafia DM: AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma. World J Gastroenterol; 2008 Jul 21;14(27):4395-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma.
  • Plasmablastic lymphoma (PBL) is a rare form of diffuse large B-cell lymphoma characterized by weak/absent expression of conventional B-cell markers and strong expression of plasma cell markers.
  • However, gene rearrangement studies confirmed a B-cell process and a more detailed immunohistochemical analysis revealed the cells stained positively for CD138 (plasma cell antigen).
  • [MeSH-major] Esophageal Neoplasms / complications. Esophageal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Medical Oncology / methods. Plasma Cells / pathology
  • [MeSH-minor] Adult. Antigens, CD20 / biosynthesis. Antigens, CD38 / biosynthesis. Cell Differentiation. Diagnosis, Differential. Endoscopy / methods. Gene Rearrangement. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Male. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Histopathology. 2007 Dec;51(6):774-7 [17944927.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1538-40; author reply 1540 [15489661.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oncologist. 2006 Jun;11(6):666-73 [16794245.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):80-1 [17213349.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1358-61 [17577502.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Hepatology. 2007 Jul;46(1):107-12 [17526021.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3176-8 [17634499.001]
  • [Cites] AIDS Read. 2007 Sep;17(9):446-7 [17902226.001]
  • [Cites] AIDS Read. 2007 Sep;17(9):448-9 [17902227.001]
  • [Cites] Oral Dis. 2007 Nov;13(6):564-9 [17944673.001]
  • [Cites] Rev Soc Bras Med Trop. 2007 Sep-Oct;40(5):582-4 [17992417.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • (PMID = 18666332.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC2731195
  •  go-up   go-down


98. Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M: Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol; 2005 Apr 28;11(16):2526-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832431.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 80168379AG / Doxorubicin; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; PIAF regimen
  • [Other-IDs] NLM/ PMC4305648
  •  go-up   go-down


99. Chen DB, Song QJ, Bao DM, Shen DH: [Anaplastic large cell lymphoma of mixed sarcomatoid and giant-cell rich variant occurring in female external genitalia: report of a case]. Zhonghua Bing Li Xue Za Zhi; 2006 Dec;35(12):759-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic large cell lymphoma of mixed sarcomatoid and giant-cell rich variant occurring in female external genitalia: report of a case].
  • [MeSH-major] Giant Cell Tumors / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Antigens, CD30 / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Melanoma / pathology. Mucin-1 / metabolism. Perineum / pathology. Perineum / surgery. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374266.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Mucin-1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


100. Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, Goldenberg DM, Bardiès M: Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer; 2010 Feb 15;116(4 Suppl):1093-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
  • [MeSH-major] Bone Marrow / radiation effects. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Radiometry / methods. Radiotherapy Dosage. Yttrium Radioisotopes / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male